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Alzheimer’s disease (AD) is a complex, multifactorial disease with a number of leading
mechanisms, including neuroinflammation, processing of amyloid precursor protein
(APP) to amyloid β peptide, tau protein hyperphosphorylation, relocalization, and
deposition. These mechanisms are propagated by obesity, the metabolic syndrome and
type-2 diabetes mellitus. Stress, sedentariness, dietary overconsumption of saturated fat
and refined sugars, and circadian derangements/disturbed sleep contribute to obesity
and relatedmetabolic diseases, but also accelerate age-related damage and senescence
that all feed the risk of developing AD too. The complex and interacting mechanisms are
not yet completely understood and will require further analysis. Instead of investigating
AD as a mono- or oligocausal disease we should address the disease by understanding
the multiple underlying mechanisms and how these interact. Future research therefore
might concentrate on integrating these by “systems biology” approaches, but also to
regard them from an evolutionary medicine point of view. The current review addresses
several of these interacting mechanisms in animal models and compares them with
clinical data giving an overview about our current knowledge and puts them into an
integrated framework.
Keywords: neuroinflammation, obesity, metabolic syndrome, type-2 diabetes mellitus, TNF, blood-brain barrier,
aging, Alzheimer’s disease
Background
Over the last century, the life span of humans living in technologically advanced societies has
expanded dramatically due to the vast knowledge gained about mechanisms underlying sustainable
health and disease, and how to implement this knowledge in the health care system. As a result,
a higher percentage of the population in these societies become centenarians as ever before, yet
certain life-style related diseases remain a problem as well. In fact, it is even questionable whether
the population as a whole is aging more healthily than before. Major obstacles to sustainable
health are metabolic diseases including obesity and diabetes mellitus (World Health Organization,
2015a,b). These diseases appear to be attracted quite easily, yet they are very difficult to treat, and
can have a devastating impact on sustainable health of individuals on the long-term (World Health
Organization, 2015a,b). It is becoming increasingly clear that diabetic and obese individuals have an
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increased risk to develop neurodegenerative diseases on the
long-term (Craft, 2005; Profenno et al., 2010). Because the
incidence of infant obesity and diabetes mellitus is on the
rise, it is expected that brain derangements like Alzheimer’s
disease (AD) will increase in the future too. AD prevalence is
estimated to reach 106.2 million people worldwide in the year
2050 (Brookmeyer et al., 2007). If one were able to delay the onset
of this disease with 12 months, this would yield 9.2 million less
cases of AD worldwide (Brookmeyer et al., 2007). A common
characteristic of metabolic diseases is a chronic and low-
grade activation of the inflammatory system (Gustafson, 2010;
Vykoukal and Davies, 2011). This inflammation may eventually
spread from peripheral tissue to the brain, and recent evidence
indeed suggests that neuroinflammation is an important causal
mechanism in AD (Hanzel et al., 2014). The current review aims
at providing an integrative neurobiological framework of the
processes that culminate from behavioral, metabolic, endocrine,
and energy balance derangements into neuroinflammation and
neurodegeneration.
Inflammation and Metabolic Diseases
Inflammation is a necessary and evolutionary conserved response
to harmful stimuli that can include tissue damage or various
pathogens that invade the host. The inflammatory response
includes numerous mechanisms and cell types (i.e., platelets,
neutrophils, macrophages, fibroblasts, endothelial cells, nerve
cells, and lymphocytes) interacting with each other to clear
out the causes of the injury, limiting ongoing infection and/or
compartmentalize damaged tissue, and to initiate tissue repair
aimed at restoring normal physiological function (Nathan, 2002).
Among others, Toll-like receptors (TLRs) on macrophages
are involved in pathogenic pattern recognition to generate
immunologically relevant responses (Takeuchi and Akira, 2010).
The release of the cytokine Tumor Necrosis Factor-alpha (TNFα)
is the prototypical response underlying inflammation and makes
up the acute phase reaction (Kmiec, 2001).Locally, TNFα
promotes cell death of damaged tissue through an apoptotic
caspase-dependent pathway (Rath and Aggarwal, 1999) allowing
repair of cells and tissue worth repairing (Winston et al.,
1999). However, TNFα also stimulates a cell survival pathway
through the nuclear factor kappa B (NF-κB) (Gupta et al.,
2005). Locally produced insulin-like growth hormone (IGF-1 and
IGF-II) orchestrates different biochemical events that culminate
into the restoration of functional integrity of damaged tissue
(Bitar, 2000). Systemically, Growth Hormone (GH) released
from the anterior pituitary influences this repair process too by
stimulating the production of IGF from the liver (Dunaiski and
Belford, 2002). IGF stimulates, for example, glucose uptake into
injured tissue (Rajpathak et al., 2009) thereby promoting energy
availability for tissue repair (Singh et al., 1998). Inflammatory
cytokines also stimulate the liver to secrete triglyceride-rich
lipoproteins, which can be used to fuel the host’s response to
infection, clear pathogens and bacteria, and may exert immune-
modulatory effects that help the innate immune response to
inflammation (Harris et al., 2000; Barcia and Harris, 2005).
Glucocorticoids acting through glucocorticoid receptors (GR)
efficiently suppress the micro-environmental IGF system (Bitar,
2000) and suppress cytokine induction downstream of TLRs
(Ogawa et al., 2005), presumably involving mitogen-activated
protein kinases (MAPK) activation (Bhattacharyya et al., 2007).
Finally, glucocorticoids reduce GH release (Tulipano et al., 2007)
through a hypothalamic somatostatin-dependent pathway. GR
belongs to the nuclear-receptor superfamily of transcription
factors, to which also the liver-retinoid receptor (LXR) and
peroxisome-proliferator-activated receptors (PPARs) belong, and
these have emerged as important modulators of innate immunity
through their effects on macrophage gene expression (Castrillo
and Tontonoz, 2004).
When the compensatory response (inflammation) is not
able to repair the damaged tissue, for example due to
chronically increased GR activation, this will turn into a
chronic condition, with continuously heightened levels of
triglycerides and cholesterol, which can lead to the formation of
atherosclerotic lesions (Esteve et al., 2005). Conditions that could
easily underlie these types of inflammations are commonly found
in obesity, and this may increase the risk for metabolic disease
like type-2 diabetes mellitus (Dandona et al., 2004; Vykoukal and
Davies, 2011; Grant and Dixit, 2015).
Metabolic Diseases
Although obesity is simply the consequence of energy intake
exceeding energy expenditure, the underlying mechanisms are
multifactorial. First of all, energy intake and expenditure are
linked with body fat as a regulated factor. This adipocentric
hypothesis–originally coined by Kennedy in the 50s of the
previous century (Kennedy, 1953)–is now well-established and
was reinforced by the discovery of the adipocyte hormone
leptin by Zhang et al. (1994). Brainstem and hypothalamic
neuropeptidergic neurocircuitry down-stream from, among
others, leptin, are involved in the homeostatic control of food
intake and energy balance, and alterations in these pathways
most often lead to secondary leptin resistance (Schwartz et al.,
2000), and often underlie weight gain (Gao and Horvath,
2008; Zeltser et al., 2012). On top of this homeostatic control
mechanism is the mesolimbic neurocircuitry involved in hedonic
aspects of food (Berridge, 2009; Berthoud, 2011). These reward
pathways can also be inhibited by leptin, thereby dampening
food-associated reward (Farooqi et al., 2007; Davis et al., 2010).
There are several other ways that affect the trajectory over which
obesity establishes itself (McAllister et al., 2009), however an
increase in the accessibility of highly palatable food items with
a highly saturated fat content and refined sugars is a leading
cause of weight gain in obesity-prone individuals, as such a
diet easily overrides homeostatic control mechanisms of energy
balance (Berthoud, 2011). At this point, it is important to
realize that these mechanisms have been shaped by evolutionary
processes, favoring genes and traits for ingestive behavior and
weight gain in times of plenty allowing survival in time of
famine (Dallman et al., 1993; Chakravarthy and Booth, 2004).
In modern industrialized societies famine is obviously not an
issue anymore, yet these genes dealing with it are probably rooted
deep in our genetic architecture (Chakravarthy and Booth, 2004),
although other theories also exist (Speakman, 2006). For these
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reasons, achieving successful weight loss is currently extremely
difficult. Eating highly palatable food can easily become addictive,
and abstinence from such food items can activate withdrawal
mechanisms (Avena, 2007; Hoebel et al., 2009). Temporary
reductions in energy intake leading to weight loss can trigger
sustainable reductions in energy expenditure that oppose further
weight loss (Rosenbaum and Leibel, 2014), and these changes
can persist long after relapse toward derailed eating behavior of
palatable and usually energy-dense food.
At some point in the progression of weight gain, adipose tissue
attracts monocytes and macrophages and changes its endocrine
functioning (Permana et al., 2006). While the exact mechanisms
are still subject of intense research (Ye, 2009; Goossens and Blaak,
2012), it is known that adipocyte/macrophage interactions lead
to production of cytokines and induce local as well as systemic
inflammatory mechanisms (Fain, 2006;Wood et al., 2009). TNFα
is known to be elevated in obese individuals, particular in those
with visceral adiposity (Tsigos et al., 1999). TNFα causes insulin
resistance by direct inhibition of insulin receptor tyrosine kinase
activity (Hotamisligil et al., 1995). In addition, IgG antibodies
linked to adipose B cell accumulation may play a role in the
development of insulin resistance in target tissue as well, since
this is attenuated by B cell depletion and conversely augmented in
lean mice that underwent IgG transfer from diet-induced obese
mice (Winer et al., 2011).
TNFα induces the secretion of other proinflammatory
cytokines, such as interleukin (IL)1β and IL6, and reduces the
secretion of the adipokine adiponectin (Wang and Trayhurn,
2006). Adiponectin increases fat oxidation in peripheral
tissue, and promotes mitochondrial biogenesis, and reduces
inflammatory markers (Yamauchi et al., 2003; Greenberg
and Obin, 2006; Lionetti et al., 2009). A reduction in plasma
adiponectin levels, at least of its high molecular weight form, has
been associated with the development of metabolic syndrome
and type-2 diabetes mellitus irrespective of changes in adipose
tissue mass (Yamauchi et al., 2001; Hojlund et al., 2006). A
comparable inhibitory effect of TNFα on the anti-inflammatory
and extracellular matrix stimulator Transforming Growth Factor
[TGF]-β has been observed (Yamane et al., 2003). The anti-
inflammatory factor IL10 conversely inhibits the TNFα system
by inhibiting TNFα converting enzyme (TACE) in monocytes
(Brennan et al., 2008) and IL10 reduces the TNFα-induced
NF-κB pathway activation as well as the apoptotic mechanisms
(Dhingra et al., 2009). Although IL10 receptors seem a promising
target for treatment of metabolic/inflammatory diseases,
however conflicting results have been found in which IL10 in
fact accelerates pancreatic Beta-cell failure (Balasa et al., 2000).
TNFα promotes spill-over of fatty acids from visceral adipose
tissue toward the liver, which contributes to elevated hepatic
triglyceride (TG) production and reduced Very Low Density
Lipoprotein clearance (Feingold et al., 1990). Consistent with this
is the finding that TNFα gene knockout mice have increased
visceral fat deposition, but have far lower hepatic fat storage
than wild-type mice (Salles et al., 2012). While the classical lipid
changes associated with the metabolic syndrome (i.e., increased
triglycerides and lipoproteins) may be envisioned as a highly
conserved evolutionary response aimed at tissue repair (Esteve
et al., 2005), these metabolic and inflammatory mechanisms can
become maladaptive and underlie the etiology of cardiovascular
and metabolic diseases (Popa et al., 2007).
Central Nervous Control of Substrate
Homeostasis
In the progression from weight gain to inflammation the
autonomic nervous system appears to play a major role. Obesity
is frequently associated with a decline in parasympathetic
activity and (regionally) increased sympathetic activity (Arrone
et al., 1997; Vaz et al., 1997; Grassi et al., 2005; Skrapari
et al., 2007; de Jonge et al., 2010). Increased sympathetic
activity is already observed before obesity establishes itself, since
diet-induced obesity prone rats can be characterized before
access to a palatable high fat diet by the hyper-responsiveness
of the sympathetic nervous system (Levin, 1993). Increased
sympathetic activity and increased blood flow through adipose
depots causes the release of fatty acids which either can be used
for metabolic purposes, or can be re-esterified in fat but also in
extra-adipose tissues including the liver and muscle (Bjorntorp,
1991). Free fatty acid (FFA) spill-over from visceral fat into the
portal circulation is caused by increased sympathetic activity in
the visceral abdominal depots, and this can easily become a self-
perpetuating process because increased FFA levels, particularly
short-chain, can activate the sympathetic limb of the autonomic
nervous system as well as the hypothalamo-pituitary-adrenal
(HPA) axis (Benthem et al., 2000). A diet with a high level
of saturated or mono-unsaturated dietary fat contributes far
stronger to abdominal weight than a diet with a poly-unsaturated
fatty acid (PUFA) content (Jang et al., 2003). Eventually, this
redistribution of fat from adipose to extra-adipose stores can
worsen insulin resistance and lead to gradual organ failure
(Unger and Scherer, 2010), provided that food intake is not
obstructed (Unger and Scherer, 2010). Whether local intra-
abdominal secretion of pro-inflammatory cytokines is increase
as a consequence of sympathetic outflow in obesity needs to
be established. This possibility may be plausible since TNFα
secretion in visceral adipose tissue is increased by sympathetic
activity induced by ischemic stroke (Wang et al., 2011). Reduced
parasympathetic activity, perhaps as a result of a shift in the
autonomic balance, is an unfavorable condition as well since
the efferent vagus nerve by means of cholinergic stimulation–
is necessary to balance cytokine production from macrophages
(Tracey, 2007).
Brain mechanisms underlying changes in autonomic outflow
in obese subjects are yet to be discovered, however the
hypothalamus may be playing a major role since it contains
preganglionic motor circuits that regulate autonomic outflow
(Luiten et al., 1985). These systems are sensitive to peripheral
hormones including insulin and leptin and can regulate
peripheral fuel fluxes (Marino et al., 2011). In addition,
enhanced afferent reflex mechanisms from adipose tissue to
the hypothalamus in obesity prone animals may contribute to
increase sympathetic activity as well (Xiong et al., 2012). Because
parts of the hypothalamus have a relatively leaky blood brain
barrier (BBB) epithelium, it is no surprise that activatedmicroglia
(i.e., which are the innate immune cells in the CNS) and increased
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levels of IgG (Yi et al., 2012) are found in the arcuate nucleus
(ARC) of the hypothalamus of mice subjected to a high fat diet
(Thaler et al., 2012; Yi et al., 2012). Analogous to the periphery,
the innate immune cells (microglia in the case of the CNS)
are important for maintaining organ physiology and relieving
cytotoxicity by clearing cell debris by phagocytotic mechanisms
(Neumann et al., 2009). In this respect the increased levels
of leptin and insulin, and several other peripheral hormones
found to be elevated in obese individuals, have neuroprotective
properties in the CNS (Signore et al., 2008). Also analogous to the
periphery is the increased secretion in the CNS of inflammatory
cytokines including TNFα as a result of feeding a high fat diet
and/or the resultant diet-induced obesity (Thaler et al., 2012).
It seems likely that increased TNFα expression in astrocytes is
more relevant for cerebral pathology than TNFα expressed in
neurons (Akassoglou et al., 1997). Increased TNFα can underlie
hypothalamic insulin and leptin resistance through the protein
tyrosine phosphatase—PTP1B pathway, which dephosphorylates
the insulin and leptin receptor associated Janus kinase (Picardi
et al., 2010). Hypothalamic insulin and leptin resistance in turn
contribute to derangements in ingestive behavior, autonomic
outflow and fuel fluxes, and eventually will augment the
inflammatory andmetabolic processesmentioned in the previous
section that fuel the vicious cycle underlying the cardio-metabolic
syndrome (De Souza et al., 2005; Posey et al., 2009; Thaler and
Schwartz, 2010; Lumeng and Saltiel, 2011).
Blood Brain Barrier Integrity
Hormonal factors like insulin and leptin not only gain access to
the hypothalamus (or other “leaky” regions like the area postrema
and subfornical organ), but virtually all brain circuits are reached
via receptor mediated transport located in the epithelium of the
BBB (Banks et al., 1996). Because plasma leptin levels increase
with higher levels of body fat (Considine et al., 1996), the level
of leptin penetrating the brain would be expected to increase as
well. This, however, is not the case since the transport system
becomes impaired by circulating triglycerides associated with
obesity and insulin resistance (Banks et al., 2004). Such a fat-
induced blockade of leptin transport across the BBB seems
maladaptive from an obesity-point of view (which in fact would
be worsened by this mechanism). Starvation, however, is also
characterized by hyperlipidemia, at least in the blood stream
(Banks et al., 2004), and the ability of triglycerides to induce
leptin resistance during famine counter the leptin-induced shift
toward use of triglycerides as an energy source and so helps
to conserve fat stores. With respect to insulin, obesity is also
associated with reduced transport across the BBB (Baskin et al.,
1985; Kaiyala et al., 2000), but this is not blocked but rather
reversed by triglycerides (Urayama and Banks, 2008). Thus, in
the case of obesity and insulin resistance, the levels of insulin
penetrating the brain can be increased, provided high levels of
circulating triglycerides.
Although the brain has a very high concentration of lipids, it
is not necessarily dependent on fatty acid oxidation as a source of
energy. Glucose is the most important energy-yielding substrate
in the CNS, which is brought across the BBB endothelium
predominantly byGLUT 1 andGLUT 3 transporters independent
of insulin (Seaquist et al., 2001). Neurons then take up glucose
directly (Patel et al., 2014), although a glucose-lactate shuttle
has also been proposed in which astrocyte nourish neurons by
lactate converted from glucose (Magistretti and Pellerin, 1999).
Glucose transport in the cortex, cerebellum, hippocampus, and
certain regions in the hypothalamus is dependent upon insulin,
via GLUT4 and GLUT8. As with the hypothalamus, insulin
resistance in these brain regions may be proposed to contribute
to hepatic insulin resistance leading to glucose intolerance and
hyperinsulinemia. As such, peripheral insulin resistance would
be adaptive in order to counter-regulate diminished glucose
availability for neuronal processes (McEwen and Reagan, 2004;
Winocur et al., 2005). Consistent with this is the idea that glucose
utilization is impaired in extremely obese Zucker compared
to lean Zucker rats (Doyle et al., 1993). The Zucker rat is a
widely used rat model for type 2 DM and is known to have
impairments in hippocampal functioning that are related to
reduction in hippocampal membrane associated GLUT4 and
insulin receptor expression (Winocur et al., 2005). In addition,
insulin dysfunctioning due to experimental (Malone et al., 2008)
or clinical (Kooistra et al., 2013; Koekkoek et al., 2014) diabetes
mellitus causes deterioration in cognitive functioning and higher
risk for stress-induced damage (Grillo et al., 2003).
Recently, Davidson and colleagues observed that hippocampal
BBB permeability of rats becomes increased (using a sodium
fluorescein penetration test) when these animals were fed a
high fat high sugar diet provided that they gained weight
(Davidson et al., 2012). Rats that did not gain weight on this
diet did not show increased leakage. The increased permeability
was found to be associated with memory impairments, in
particular hippocampus dependent learning (Davidson et al.,
2012). Obviously, a leaky BBB exposes the brain to “secondary”
risk factors that easily can do harm, and it is plausible that
this underlies the obesity-associated inflammatory process, as
was discussed previously. Monocyte/macrophage of which the
levels are found to be elevated in obesity could be transported
across the BBB and may facilitate this process, although this
idea needs to be confirmed (Freeman et al., 2014). Associations
between cognitive impairment and obesity are also found in the
human literature (Fitzpatrick et al., 2013; Vainik et al., 2013).
Causal mechanisms by which obesity affects BBB integrity are
still lacking, however it may be hypothesized that the increased
leakiness is caused by cytokines that build up over the course
of weight gain (Banks, 2005). In particular the proinflammatory
adipokine lipocalin-2 may be important as this hormone is
upregulated in obese humans and rodents (Wang et al., 2007),
and accumulation of deamidated lipocalin-2 in arteries causes
vascular inflammation and endothelial dysfunction in dietary
obese mice (Song et al., 2014). While it is quite difficult to get
cytokines in the CNS, they could affect penetration of other
compounds. Such a possibility may exist for insulin, of which
the BBB transport is increased upon lipopolysaccharide-induced
inflammation (Banks, 2005). Increased BBB transport of insulin
would make sense, because insulin resistance would counter
its earlier mentioned neuroprotective effects. BBB endothelial
cells express nuclear receptors that play a role in expression
of tight junction protein, cytokine and transporter genes (Pan
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et al., 2011). In this respect, locally released inflammatory
factors including TNFα may be a response to upregulate glucose
utilization in astrocytes, turning them into a more oxidative
state and actively contribute to increased neuronal vulnerability
(Gavillet et al., 2008). This inflammation may then in turn
causes the BBB to be weakened (Freeman et al., 2014). An
increased oxidative state would lead to increased production of
reactive oxygen species (ROS) and incur damage leading to a
decline in cognitive function (Lu et al., 2004). Recently, Freeman
et al. (2013) observed that high fat dietary-induced obese mice
had significantly higher levels of total ROS, superoxide, and
peroxynitrite in cortical regions compared to mice on a low fat
control diet. The level of oxidative stress was highly related to
the level of adiposity, and to impaired cognitive performance
(Freeman et al., 2013).
Neurodegenerative Processes
The magnitude of the above mentioned derailments clearly
predicts the risk for attracting dementia (Tolppanen et al., 2014),
even independent of genetic and early life environmental factors
(Xu et al., 2011). Thus, the collective and culminated neuronal
damage that has occurred over time will inevitably lead to signs of
dementia, as a function of age. Secondly, repair mechanisms may
become less effective with age too (O’Neill, 2013), which then also
contribute to the etiology of neurodegeneration.
GH/IGF1
As mentioned in the introduction, the GH/IGF axis plays an
important role in tissue repair and growth, and reductions in the
activity of this system with age (Ho and Hoffman, 1993) may be
relevant for age-related diseases. A reduction in GH secretion
begins after the pubertal maximum and is correlated with an
increased percentage of total body and visceral fat and decreased
physical fitness (Veldhuis et al., 1997). Bartke suggested that
the reduction in the GH/IGF axis is a necessary mechanism to
protect against cancer (Bartke, 2008). Maintenance of the activity
of the GH/IGF axis throughout life would be counter-productive
in terms of hyperfunction potentially involving the mTOR
pathway and this would increase damage rather than reducing it
(Blagosklonny, 2013). Both dietary- and age-associated increases
in adiposity are linked to a reduction in spontaneous (Vahl
et al., 1997) and stimulated (Makimura et al., 2008; Cordido
et al., 2010) GH secretion. This results in an overall reduction
in circulating levels of GH, and these too low levels may have
some repercussion for the aging process. The cause of impaired
GH secretion following dietary-induced weight gain is under
intense investigation (Steyn et al., 2013). A decreased pituitary
GH synthesis and/or release as well as an increased GH clearance
from the blood may explain the low circulating GH levels in
obese rats (Dubey et al., 1988; Ahmad et al., 1989). While caloric
excess results in lower GH levels, this is found to be associated
with higher circulating IGF-1 and insulin levels and lower insulin
sensitivity as a result of the associated weight gain (Woods et al.,
2003; Sebert et al., 2005).
There is considerable evidence that GH acts in the CNS to
affect cognitive processes. Humans that lack the GH receptor
(GH-R) show a significant loss of spatial discrimination speed
and efficiency compared to their normal relatives (Kranzler
et al., 1998). This has to some extent been confirmed in animal
studies (Li et al., 2011), although opposite effects also have been
mentioned (Banks et al., 2010). Furthermore, GH appears to be
neuroprotective against several forms of brain injuries (Hanci
et al., 1994; Winkler et al., 2000; Scheepens et al., 2001; Enhamre-
Brolin et al., 2013). A potential role for GH in development of the
CNS is supported by the widespread distribution of GH and its
receptor within the developing CNS (Garcia-Aragon et al., 1992;
Lobie et al., 1993). The effects of GH in the CNSmay be mediated
via IGF-1, analogous to the effects seen in peripheral tissue
as mentioned above. Indeed, GH or IGF1 treatment increases
hippocampal neurogenesis (Aberg et al., 2000; Aberg, 2010). IGF1
(D’Ercole, 1996; Folli et al., 1996) and IGF1R (Yan et al., 2011) are
expressed locally in diverse areas throughout the brain. Central
administration of IGF1 decreases depressive-like behavior and
brain cytokine expression, including TNFα and IL6 in mice (Park
et al., 2011).
Recently it was shown that the GH stimulatory effects
on cognitive function in rats with traumatic brain injury
is associated with increments of hippocampal and prefrontal
Brain Derived Neurotrophic Factor (BDNF) mRNA expression
and its receptor TrkB mRNA expression (Zhang et al.,
2014). BDNF is known to increase neurogenesis and neuronal
connectivity (Mattson and Magnus, 2006), and a decline in
hippocampal BDNF secretion might contribute to age-related
impairment in cognitive performance (Hattiangady et al., 2005).
Acutely elevating levels of IGF-1 in mice by microinjection
in hippocampus was found to stimulate BNDF and cognitive
performance while the opposite was observed in mice treated
with IGF-1 antiserum (Trejo et al., 2007). Neuronal transport of
BDNF, at least in isolated hippocampal tissue, has been shown to
rely on the insulin signaling cascade including phosphorylation
of PKB/Akt (Takach et al., 2015). While BDNF levels in the
CNS declines with age, diet-induced obesity lowers hippocampal
synaptic plasticity, BDNF levels and cognition (Stranahan et al.,
2008) by itself, at least in rodents. Reduced GH and IGF1 levels,
insulin resistance, as well as inflammatory markers may all
contribute to this effect (Cotman, 2005).
β-Amyloid Protein
Insulin resistance and thus increased levels of circulating insulin
have repercussions in the CNS. The breakdown of insulin in the
CNS requires insulin-degrading enzyme (IDE), a peptide that
also degrades β-amyloid protein (Aβ). Highly increased levels
of insulin therefore attenuate Aβ clearance (Ho et al., 2004).
Aβ is derived from a larger transmembrane amyloid precursor
protein (APP) (Cras et al., 1991) of which the function is not
exactly known. APP consists of a large extracellular domain, a
hydrophobic transmembrane domain, and a short cytoplasmic
carboxyl terminus. The Aβ sequence lies partially outside the
cell membrane. A heavily glycosylated region of APP lies NH2-
terminal to the Aβ sequence. This sequence is highly conserved
and is nearly identical in species from Drosophila to human
(Suh and Checler, 2002). Aβ peptides are natural products
of metabolism in their monomeric form ranging from 36 to
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43 amino acids (Querfurth and LaFerla, 2010), and probably
serve as an antimicrobial peptides (AMPs) to stimulate the
innate immune response (Soscia et al., 2010). Aβ40 is the most
common form and is much more prevalent then the aggregation-
prone Aβ42 species. Proteolysis of APP is required to obtain
these peptides, and is facilitated by sequential enzymatic actions
of beta-site APP cleaving enzyme 1 (BACE-1), a β-secretase,
and γ-secretase (Querfurth and LaFerla, 2010).While being
beneficial against bacterial infections (Soscia et al., 2010), Aβ
can form multimers or fibrils which form the core extracellular
amyloid deposits. These are surrounded and attacked by reactive
astrocytes, and reactive microglia (Cras et al., 1991; Dournaud
et al., 1995), probably as an adaptive response to confine
infectious hazards. This process, however, can induce neuronal
cell death, and will eventually result in cognitive impairment, loss
of memory functions and physical deterioration, which are all
irreversible (Belkhelfa et al., 2014). Correlated with fibrillization
are initiation of toxic and neurotoxic cascades (Dumery et al.,
2001). Aβ elicits this toxicity in its oligomeric form, and these
cytotoxic properties are mediated via a ROS pathway (Dumery
et al., 2001). Indeed this has also been confirmed in recent
research, which stated that the formation of ROS is an early
response to the oligomeric derivatives of Aβ (Giordano et al.,
2014). Other studies show that amyloid plaques are colocalized
with a variety of pro-inflammatory proteins and clusters of
reactive astrocytes and activated microglia (Eikelenboom et al.,
2010). This leads to suggest that, besides activation of the ROS
pathway, a chronic inflammatory response is activated by the
formation of Aβ-plaques, which may also underlie neuronal
cell death and impaired cognition. Indeed, Jaeger et al. showed
that mice with lipopolysaccharide-induced inflammation had
increased influx and decreased steroid-independent eﬄux of
central Aβ (Jaeger et al., 2009), which clearly would augment the
etiology of neurodegenerative processes.
Neurofibrillary Tangles
Another neurodegenerative process relates to the production of
neurofibrillary tangles (NFTs). These tangles are the result of
a misconfiguration of microtubule stabilizing protein called tau
and its associated microtubule-associated protein tau (MAPT).
NFTs are made up of paired helical filaments (PHF) (Wischik
et al., 1988; Dournaud et al., 1995), which can accumulate
within neuronal cell bodies. This can lead to de-stabilization
and eventually dissociation of microtubules. Furthermore,
intermediate aggregates of tau, like Aβ, are cytotoxic and can
impair cognition (Santacruz et al., 2005). This impairment might
be primarily caused by synaptic failure. Indeed, subjects with
mild cognitive impairment, synapses in the hippocampus begin
to decline (Querfurth and LaFerla, 2010). Furthermore, the
process of aging itself is also associated with synaptic loss,
particularly in the dentate region of the hippocampus (Querfurth
and LaFerla, 2010).As mentioned earlier, chronic inflammation,
which leads to induction of senile plaques (SPs) and NFTs, is a
key element in these neurodegenerative processes (Eikelenboom
et al., 2010). Supporting evidence for this idea comes from a study
that SPs are the source of the infection of a chronic inflammatory
response that is induced by fibrillization of Aβ, which in turn
activates an innate immune response (Eikelenboom et al., 2010).
The Aβ peptide itself is able to induce a local inflammatory
response, involving the binding of fibrillar Aβ to complement
factor C1, which then activates canonical complement pathways
in an antibody-independent fashion (Eikelenboom et al., 2006).
This activation can play an important role in the migration and
activation of microglial cells which express complement factors.
These microglial cells in turn show a high secretion level of IL6
and TNFα (Familian et al., 2006; Eikelenboom et al., 2010) in the
case of high concentration of Aβ.
In type-2 diabetic patients, the production of Aβ is
exacerbated (Sims-Robinson et al., 2010). Furthermore, studies
in mice have revealed that in both type 1 and particularly type
2 diabetes the phosphorylation of tau is increased (Kim et al.,
2009). In this case the consideration must also be made about
the fact that cognitive deficits might not only be caused by tau
phosphorylation, but also by toxicity of hyperglycemia, or by
impairment of insulin signaling per sé. Specifically, glycosylation
of O-linked β-N-acetylglucosamine (GlcNAcylation) underlies
the etiology of glucose toxicity in diabetes mellitus, and also
plays a role in neurodegenerative processes. The decreased level
of GlcNAcylation under diabetic conditions therefore suggests
an attenuating role on tau phosphorylation and tau-induced
neuronal death (Liu et al., 2009). Patients with type-1 diabetes
mellitus exhibit most problems with cognition because of a
systemic insulin deficiency. Changes in spatial learning and
hippocampal long-term potentiation (LTP) are indeed seen in
animal models of diabetes mellitus (Sims-Robinson et al., 2010).
These changes can be normalized or prevented by insulin
replacement therapy. Within the case of type-2 diabetes mellitus
cognitive impairment and neurodegeneration could be caused by
a loss of sensitivity of insulin receptors which might lead to an
increased expression of Aβ and tau (Sims-Robinson et al., 2010).
Furthermore, a decrease in insulin receptor signaling leads to
inhibition of PKB/Akt, which normally dephosphorylates (i.e.,
activates) glycogen synthase kinase 3β (GSK-3β), and that finally
leads to tau hyperphosphorylation (Sims-Robinson et al., 2010).
Activation of GSK-3β is also highly relevant to TNFα, since TNFα
can inactivate PKB/Akt via TNRF1, which leads to inactivation of
GSK-3β. Finally, down-regulation of GSK-3β leads to apoptosis
(Takada et al., 2004). Collectively, this leads to the suggestion that
there is a connection between insulin resistance and a potential
neuroinflammatory response via up-regulation of TNFα.
Balancing TNFα
Important for consideration is the fact that the binding and
signal transduction of TNFα is mediated by two TNF receptors;
i.e., TNF-Receptor 1 (TNFR1) and TNF-Receptor 2 (TNFR2)
(Zettlitz et al., 2010). TNFR1 excerpts axonal and neuronal
damage through its pro-inflammatory effects, which are clearly
observed under chronic inflammatory situations (Fischer et al.,
2011). TNFR2, however, is associated with a neuroprotective
effect against excitotoxic insults, although this has to be
confirmed in vitro (Marchetti et al., 2004). TNFR2 is considered
as an activator of the NF-κB pathway, which exerts gene
activation and anti-apoptotic signaling, but this also has a pro-
inflammatory response via TNFR1 (Kontermann et al., 2008).
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TNFR1 contains a death-domain (DD), which for that reason
can mediate apoptotic signals, while TNFR2 can mediate cell
survival and neuronal protection via the NF-κB pathway (Wajant
et al., 2003). This crosstalk is mostly mediated via the TNF-
receptor associated factor (TRAF) family, with TNFR1 activation
gene expression via indirect recruitment of TRAF1, and TNFR2
recruiting TRAF2. These factors form the basis for TNF cytokine
signaling (Inoue et al., 2000). Thus, there is a dual role of
TNFα on neuronal homeostasis, which is mediated via these two
receptors.
The finding that TNFα is not solely produced by macrophages
and other immune-regulating cells, but also by adipose tissue
in obese (and insulin-resistant) mice (Moller, 2000) and
even in human adipocytes in individuals with obesity or
hyperinsulinemia, may suggest a causal link between processes
in the brain and the periphery. Weight loss in obese individuals
correlates with a reduction of circulating TNFα levels and
other inflammatory cytokines (Bruun et al., 2003), which may
eventually lead to a reduced activity of neuroinflammatory
pathways in the brain (Ghanim et al., 2012). Thus, this evidence
collectively suggests that obesity and/or diabetes mellitus induces
a neuroinflammatory response which upregulates TNFα and
other pro-inflammatory cytokines that via multiple pathways
leads to an increased risk of neurodegeneration.
Progression toward Alzheimer’s Disease
The processes and pathways mentioned above can at some
point lead to such cognitive impairments that they become
classified as AD. Memory loss is the most presenting symptom
found in people developing AD (Burns and Iliffe, 2009). Also
present are symptoms as poor sleep quality (Landry and Liu-
Ambrose, 2014), emotional changes, anxiety and depression
(Burns and Iliffe, 2009). This cognitive deterioration furthermore
coincides with the neuropathological staging of AD (Braak and
Braak, 1991; Schroeter et al., 2009). At the age AD manifests
itself (frequently around the age of 65) (Brookmeyer et al.,
1998), the neurodegenerative processes are already ongoing for
many years, or perhaps even decades, yet its progression can
differ substantially between patients. Advancing dementia in
AD correlates strongly with the disproportional loss of synapses
between neurons (DeKosky and Scheff, 1990). The number of
NFTs is directly related to the severity of AD, and could serve as
a pathologic marker (Querfurth and LaFerla, 2010). The initial
indication that led to show the contribution of TNFα in AD
was the presence of TNFα in the vicinity of SPs in post-mortem
AD brains (McCoy and Tansey, 2008). This co-localization of
TNFα and SP was also seen in brains of transgenic mice that
expressed APP. The fact that transgenic mice with deletion of
TNFR1 show a significant decline in microglia activation, BACE1
activity, Aβ pathology, less memory deficits and less neuron loss
indeed suggest a role for TNRF1 in the pathogenesis of AD (He
et al., 2007). A potent and effective method of treating AD via
the TNF signaling pathway is therefore anticipated. Targeting the
TNF signaling pathway in neurodegenerative diseases such as AD
is a strategy, which has received increasing amounts of interest.
Human-specific reagents, which target the neurodegenerative
and neuroprotective effects of respectively TNFR1 and TNFR2
are for example ATROSAB, a human specific antagonistic TNFR1
antibody (Zettlitz et al., 2010), and Tenascin C single chain TNF
(TNC-scTNF) (Fischer et al., 2011), a TNFR2 selective agonist.
By selectively inhibiting TNFR1 and/or activating TNFR2, the
neuroprotective effects of these receptors might be of use as a
possible break on the neuroinflammatory pathway involved in
neurodegenerative processes.
Several studies have already confirmed that patients with
diabetes mellitus have an increased risk of developing AD
(Brands et al., 2005; Biessels et al., 2006). About 80% of
patients with AD exhibit symptoms of glucose intolerance or
diabetes mellitus (Janson et al., 2004). Several factors associated
with obesity including hyperglycemia, insulin resistance, glucose
intolerance, atherosclerosis, adiposity and hypertension (Haan,
2006) can increase the risk for attracting AD too. Interestingly,
being overweight or obese more strongly increases the risk
for developing AD later in life, than being overweight or
obese at late life (Emmerzaal et al., 2015). In their meta-
analysis on epidemiological studies on the link between obesity
and AD, Emmerzaal et al concluded that “current trends of
more overweight and obesity in childhood and adolescence
may translate to longer exposure of the brain to potentially
detrimental vascular and metabolic effects of adipose tissue. This
increased size of the population at risk in combination with
longer survival, continues to underscore the importance and
necessity of research in this field” (Emmerzaal et al., 2015). In the
following paragraphs, a number of factors are described which
have been mentioned to affect the risk for attracting AD.
ApoE
Early-onset familial AD (EOAD) (under 65 years of age) is
usually the cause of an age-related dichotomy of rare autosomal
dominant mutations (Bertram et al., 2007). The risk of late-
onset AD (LOAD) (over 65 years of age) is on the other hand
increased by genetic variants of which the penetrance is relatively
low, but prevalence high (Tanzi, 1999). LOAD probably accounts
for about 95% of all AD cases. The one genetic factor that has
been firmly established to underlie LOAD is the ε4 allele of
Apolipoprotein E (ApoE, ApoE-ε4). ApoE is a protein that is
mainly involved in the transport of cholesterol (Strittmatter et al.,
1993). The production of ApoE is mediated by astrocytes, which
then secretes it into the CNS in high-density lipoprotein (HDL)-
like particles. ApoE levels are upregulated following injury and
during development, so it functions mainly in growth and repair
(Strittmatter et al., 1993). An increase of ApoE is also seen in
several chronic neurodegenerative diseases, such as AD, in which
ApoE binds to SP and NFT (for review see Liu et al., 2013).
The suggestion that ApoE serves as a genetic predisposing factor
comes from the observation of high levels of ApoE mRNA in
brains of patients with AD (Strittmatter et al., 1993). Through
the action of the ATP-binding cassette transporter (ABCA1) and
other related transporters, ApoE is lipidated. ABCA1 normally
serves to transfer phospholipids and cholesterol to ApoE (Jiang
et al., 2008). Research suggests that the lipidated form of ApoE
acts to enhance the clearance of Aβ peptides from the brain, in
the form of elevated proteolytic breakdown. There are multiple
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isoforms of ApoE, of which ApoE-ε4 is one of these. The ApoE-
ε4 isoform differs structurally from other isoforms resulting in
the fact that this ApoE-ε4 protein mediates neuronal death and
neurodegeneration, and thus not have the same Aβ proteolytic
properties (Bagyinszky et al., 2014).
As opposed to LOAD, EOAD is characterized by mutations
in the APP gene, presenilin 1 (PSEN1) gene and presenilin
2 (PSEN2) gene. Mutations in these genes might result in
alteration of Aβ production (both Aβ40 and Aβ42), which can
lead to apoptosis and dementia (Bagyinszky et al., 2014). The
involvement of the APP gene has been discovered in patients with
Down syndrome who are prone to develop AD at a very early age.
Triplication of the APP gene, which is localized on chromosome
21, is the cause of this greater predisposition of early onset of AD
pathology in patients with Down syndrome (Bagyinszky et al.,
2014).
Because of the involvement of ApoE in lipid-transport and
its role in the clearance of Aβ, this is a significant risk factor
to discuss. ABCA1 expression, because of its lipidation action
of ApoE, is a crucial transporter-protein. The expression of
both ABCA1 and ApoE are induced by the Liver X receptor
(LXR), which is a ligand-activated transcription factor (Jiang
et al., 2008). LXR acts as a sensor for cholesterol and is activated
by oxysterol (oxidized derivatives of cholesterol), which results
in a rapid increase of lipidated forms of ApoE (Cao et al.,
2007; Jiang et al., 2008). This is where lifestyle factors first
come into play in the onset and progression of AD, because
it suggests a strong link between AD and dietary habits, the
cardiovascular system, and metabolism. For example, it has
been shown that high systolic blood pressure at midlife is
a significant risk for developing AD later in life (Kivipelto
et al., 2001). Furthermore, the same research also revealed a
link between high serum cholesterol concentrations as a risk
for AD. Combining these two risk factors probably contribute
in a synergistically fashion to the proneness of AD. The
mechanism behind these interactions however remains quite
complex, and clearly more research is necessary to unravel them.
It may however be speculated that a high cholesterol intake
elevates the serum cholesterol levels, which create an overload
of ApoE, which then leads to a down-regulated proteolysis
of Aβ (Puglielli et al., 2003). Susceptibility for AD increases
further in carriers of the ApoE-ε4 SNP, because of the higher
cholesterol content of the ApoE-ε4 lipoproteins. Furthermore,
in patients with AD, lecithin cholesterol acyltransferase (LCAT)
activity is significantly reduced, suggestively by the ApoE-
ε4 SNP (Puglielli et al., 2003). LCAT is an enzyme that
catalyzes the process that clears cholesterol from peripheral
cells.
TNFα may interact with ApoE, at least in atherogenic
processes in mice that were feeding a diet rich in saturated
fat and cholesterol (Ohta et al., 2005). This upregulation of
TNFα is probably involved in the inflammatory responses in
atherogenesis, mediatedmainly by its soluble form of the TNFR1.
Whether this TNFR1 mediated pathway provides the link
between a high fat/cholesterol diet and the neuroinflammatory
responses, which can promote the onset of AD remains to be
investigated.
Saturated Dietary Fat
As mentioned earlier, a diet with a high level of saturated
or mono-unsaturated dietary fat contributes far stronger to
abdominal weight than a diet with a poly-unsaturated fat
content (Jang et al., 2003). The statement that a high fat
diet may be a contributing factor in neuroinflammation is
partially established by the fact that a high fat diet has been
reported to induce a CNS inflammatory response by means
of an enhanced systemic inflammation (Timmermans et al.,
2014). Furthermore, numerous previous studies have shown
the effect of high fat feeding on microglial activation and
overall neuroinflammation in specific brain regions (Thaler and
Schwartz, 2010; Fuente-Martin et al., 2012; Thaler et al., 2012). In
accordance, considering the risk factors age and obesity, which
are both associated with neuroinflammation (Labrousse et al.,
2012; Makki et al., 2013), also seem to both have a lowering on
overall testosterone levels inmales (Teerds et al., 2011; Jayaraman
et al., 2014) which then in turn also affects neuroinflammation
in rodents (Jayaraman et al., 2014). Particularly high levels of
saturated fatty acids (SFA) may increase the risk of dementia and
even AD later in life (Kalmijn et al., 1997; Morris et al., 2004;
Eskelinen et al., 2008), suggestively via mechanisms involving
ApoE-e4 (Laitinen et al., 2006) and may also be conveyed by
inflammatory mechanisms (James et al., 2000). The same study
suggests the counteracting effect of omega-3 poly-unsaturated
fatty acid (n3-PUFA) ingestion on systemic inflammatory
cytokines such as TNFα (James et al., 2000). Recent studies
concur with this suggestion, showing that specific n3-PUFAs
exert profound anti-inflammatory effects on the brain after
neuroinflammatory challenges (Bazan, 2007; Belayev et al., 2009;
Orr et al., 2013; Zendedel et al., 2015). Particularly decreased
levels of the n3-PUFA docosahexaenoic acid (DHA) correlate
with cognitive impairment and are established to be decreased
in AD (Prasad et al., 1998; Suzuki et al., 1998; Bazan, 2007; Orr
et al., 2013). It is suggested that Western diets do not provide the
aged brain with an optimal supply of these n-3 PUFAs (Woo,
2011; Cutuli et al., 2014). Even more convincing are the facts
that the aged brain shows a reduced capacity of n-3 PUFAs to
pass the BBB and to convert shorter chained fatty acids to longer
fatty acids (Yehuda, 2012; Cutuli et al., 2014). There is a possible
beneficial effect of n-3 PUFA supplementation (including DHA)
that may improve hippocampal functioning in aged mice (Cutuli
et al., 2014). Unfortunately, the aforementioned ApoE-e4 carriers
appear to be unresponsive to the protective effect of n3-PUFA
supplementation (Barberger-Gateau et al., 2011). Furthermore,
n-3 PUFA supplementation seems inefficient at old age to prevent
cognitive decline or when AD has been diagnosed already,
and should thus be regarded as preventive rather than curative
(Cederholm et al., 2013; Jiao et al., 2014)
Sedentary Lifestyle
Leading a sedentary life style is known to be a factor that
contributes to weight gain, an at a population level a reduction
in obesity and sedentary living increases the number of years
without cognitive impairment (Anstey et al., 2014). Chronic
exercise is also associated with preservation of overall cognitive
function and prevention of dementia (Zhao et al., 2014). It is
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difficult to dissociate the beneficial effects of physical activity
on cognitive function independent of its effects on peripheral
endocrine and cardiometabolic health. However, exercise is a
proven stimulus of GH release and an acute bout of exercise
stimulates a significant GH pulse (Pritzlaff et al., 2000; Wideman
et al., 2002; Godfrey et al., 2003), although the effects in
the elderly seems diminished (Marcell et al., 1999). However,
resistance training over a 12 week exercise protocol in elderly
people promoted an increase in acute GH response, possibly
owing to an increase ability to exert oneself (Craig et al.,
1989). Thus, exercise is a potent stimulator of GH and IGF1
release and it may take a few hours to recover back to baseline
levels (Kanaley, 2008). It is speculated that the mechanism
responsible for exercise-induced GH release is a suppression
of hypothalamic secretion of somatostatin and possibly during-
high intensity exercise an augmented hypothalamic secretion of
GHRH. The primary function of GH release during exercise
may be post exercise protein synthesis (Kanaley, 2008). Basal
levels of IGF-1 decrease during aging (Yamamoto et al., 1991;
Ruiz-Torres and Soares de Melo Kirzner, 2002; Trejo et al.,
2004). Trejo et al. (2002) have pointed out that physical activity
increases the uptake of IGF into CNS, and IGF may activate
the synthesis and release of nerve growth factors (NFGs). In
rodent studies, exercise is known to stimulate BDNF expression
and release in the hippocampus, in this is associated with
increased cognition and increased PKB/Akt phosphorylation
(Aguiar et al., 2011). In addition, wheel-running aged mice had
attenuated microglial proliferation and increased expression of a
proneurogenic hippocampal phenotype compared to sedentary
mice (Kohman et al., 2012). Stranahan et al. observed that
exercising mice had increased hippocampal BDNF levels and
associated increased spine density (i.e., compared to sedentary
mice), and this effect was also observed in genetically obese mice,
yet less outspoken (Stranahan et al., 2008). Interestingly, elevating
hippocampal BDNF signaling by the TrkB receptor increases
“browning” of white adipose tissue and adaptive thermogenesis
(Cao et al., 2011), which would constitute a positive feedback, and
may explain the positive effects of physical activity on metabolic
as well as cognitive health.
Finally, long-term exercise treatment reduces oxidative stress
in the hippocampus of aging rats (Marosi et al., 2012).
Furthermore, it has also been shown in a mouse model
that exercise can attenuate the DNA binding of NF-κB,
which essentially suggests a decrease in inflammation, possibly
involving TNFα. Healthy volunteers who received an injection
with a low dose of Escherichia coli endotoxin showed a two- to
threefold increase of circulating TNFα, and this was significantly
reduced by exercise (Petersen and Pedersen, 2005). Because
ROS and inflammatory cytokines were discussed earlier to be
involved in an early response to the oligomeric derivatives
of Aβ, exercise would therefore slow progression of AD.
Exercise can also increase vagal tone, which suggestively reduces
the inflammatory response because of the aforementioned
cholinergic anti-inflammatory response (Woods et al., 2012). In
summary, exercise affects multiple organ and organ systems,
which contribute via different mechanism to delay the onset and
progression of AD.
Stress
It was mentioned earlier that obesity is associated with an
increase in sympathetic activity (Arrone et al., 1997; Skrapari
et al., 2007; de Jonge et al., 2010) and HPA axis activity
(Bjorntorp, 1991; Benthem et al., 2000), which both could
result from a reflex mechanisms involving fatty acid spill-over
from abdominal fat depots toward the liver. Psychological or
psychosocial stress also lead to enhancement of sympathetic
activity and HPA axis activity, which are required to fuel a
fight/flight response (Koolhaas et al., 2011). In our society of
plenty, however, fight/flight responses are no solution for our
stressors to which we are exposed. Furthermore, living in a
complex society can impose stressors that are chronic in nature.
As a result, stress responses become extended, and without the
physical component of stress would incur damage (McEwen and
Wingfield, 2003), with the higher spill-over of fat and glucose
propagating sympathetic and HPA axis activity. Eating highly
palatable food items can be rewarding and may be protective
against deterioration of mood (Dallman, 2010), but would not
fuel physical activity, and thus would enhance cardiometabolic
damage. Reader et al used a repeated social defeat (RSD) stress
model for induction of chronic psychological/psychosocial stress
and observed increased microglial activation, which is a proxy
for neuroinflammation (Reader et al., 2015). In a psychosocial
stress model, submissive animals develop depressive-like
behavior (Norman et al., 2010), which is often associated with
an increased inflammatory state (Cohen et al., 2012). The
mechanistic links between inflammation and depression are
well understood (Norman et al., 2010; Capuron and Miller,
2011; Reader et al., 2015), and may involve HPA axis activity
and sympathetic activity (Reader et al., 2015). A permissive
action of the endothelial IL1 receptor and stress-induced
neuroinflammation and anxiety-like behavior was recently
established (Wohleb et al., 2014a), and monocyte trafficking
across the BBB probably plays an important role in this link
(Wohleb et al., 2014b).
Increasing parasympathetic activity might have beneficial
effects on inflammation, as reviewed by Tracey (2007). As already
mention, Tracey exposed the effects of stimulating the vagus
nerve and administrating nicotine which inhibits TNFα release
and various other pro-inflammatory cytokines (Borovikova et al.,
2000; Wang et al., 2003; Tracey, 2007; Pavlov and Tracey,
2012). Increasing parasympathetic activity would also normalize
autonomic disbalance in the obese state, in which sympathetic
activity is known to be increased (Arrone et al., 1997; Vaz et al.,
1997; Grassi et al., 2005; Skrapari et al., 2007; de Jonge et al.,
2010). Thus, by increasing parasympathetic tone, the vicious
cycle including increased fatty acid spill-over and increased
sympathetic and HPA activity would be broken. Indeed, vagal
nerve stimulation (VNS) has been used in the treatment of
AD. Vonck et al. (2014) recently gave an overview of the
studies addressing VNS, and alluded to the idea that anti-
inflammatory pathways in the CNS are set in motion by VNS
that are beneficial for AD patients. Whether this would also
work under conditions of psychosocial or psychological stress is,
to our knowledge, unclear. Because stress augments Aβ release
and amyloid aggregation in animal models of AD (Dong and
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Csernansky, 2009; Srivareerat et al., 2009) further research in this
field is therefore warranted.
Circadian Disorders
Finally, the role of circadian dysregulation as a considerable
risk factor for neuroinflammatory responses deserves some
attention, as it will increase the risk of neurodegenerative
diseases. Circadian disorders are primarily caused by deficits
in the circadian system driving the 24 h rhythms in body and
brain. In the brain, the hypothalamic suprachiasmatic nucleus
(SCN) has been identified as the master circadian clock driving
many other circadian clocks and clock systems. One important
function of this clock is the regulation of the sleep/wake
cycle. Disruptions of the circadian clock will lead to sleep
disturbances, and these sleep disturbances (e.g., sleep loss) in
turn cause a neuroinflammatory response (Wisor et al., 2011).
As such, circadian disorders can be viewed as a distinctive
pro-inflammatory factor. It has been recently recognized that
improvements in circadian rhythm functioning as well as
appropriate sleep interventions should therefore be further
explored in order to delay neurodegenerative progression, and
notably so in case of AD (Landry and Liu-Ambrose, 2014). The
age-related alterations in innate immunity and chronic systemic
inflammation cause a persistent neuroinflammatory state. This
state accelerates degenerative diseases via its dysregulation
of clearance mechanisms of misfolded or damaged neuronal
proteins and loss of axonal integrity linked to tau-pathology
(Krstic and Knuesel, 2013). In a study comparing the SCN
of young and aged mice, it was found that neurons and glial
cells of the SCN are sensitive to inflammatory signals (Sadki
et al., 2007). The response of the aged glial cells in the SCN is
markedly more pronounced to cytokine exposure (Bentivoglio
et al., 2006). In the aged SCN, it is notably the circadian output
toward other hypothalamic nuclei that is disrupted (Van der Zee
et al., 1999; Weinert, 2000). A successful intervention would
be the one, which improves circadian output pathways. One
such intervention could be exercise, as it has been shown to
strengthen the circadian system in aged mice (Leise et al., 2013).
The cholinergic system provides input to the circadian clock,
and it has been hypothesized that reduced cholinergic input
FIGURE 1 | Detrimental and healthy life style factors respectively
stimulate and reduce the risk for attracting obesity, the metabolic
syndrome and type-2 diabetes mellitus. These factors also have a
stimulatory effect per sé on age-related damage and accelerate senescence.
Associated with obesity, metabolic syndrome, and type-2 diabetes mellitus,
there is inflammation, insulin resistance, and hyperinsulinemia (i.e., depending
on the stage of type-2 diabetes mellitus). Hyperactivity of the sympathetic
nervous system and HPA axis worsen insulin resistance and deteriorate
cardiovascular health. At the level of the brain, several mechanisms are set in
place, among which neuroinflammation and insufficient brain fueling are
proposed to backfire and contribute to increased sympathetic and HPA
activity as well. Finally, these processes lead up to Aβ aggregation, Tau
hyperphosphorylation, and NeuroFibrillary Tangle (NFT) deposition, which
also backfire and culminate into AD. (1) Upregulating ketone provision to the
brain, (2) exercise/physical activity, and (3) increasing the level of n-3 PUFAs
(by diet supplementation as preventive action) slow the progressive stages in
the disease, and are also proposed to reduce the backfiring effects, which
puts a brake on the vicious cycles in the etiology of AD.
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hampers several circadian clock-dependent processes, including
sleep as well as learning and memory (Hut and Van der Zee,
2011; Mulder et al., 2013). As acetylcholine release inhibits
the production of proinflammatory cytokines by microglia
(Shytle et al., 2004), the cholinergic system has been suggested
to function as a mediator in neuroinflammatory responses.
However, neuroinflammation has been shown to selectively
disrupt the cholinergic system (Araujo et al., 1989). Hence,
increasing levels of neuroinflammation impair the cholinergic
system and reduce its inhibitory role on proinflammatory
cytokine production, further worsening the situation. Taken
together, the aging SCN is at increasing risk of becoming
damaged by (excessive) neuroinflammation. This will lead to
(further) circadian dysregulation, and as a result increased
disturbance of the sleep/wake cycle and hence increasing
excessive neuroinflammatory responses even further. Obesity
is known to be associated with circadian (Roenneberg et al.,
2012) and sleep (Kudlow et al., 2013) derangements, and
circadian disturbances inflate the metabolic syndrome (Staels,
2006). Improving the function of the SCN and maintaining
the expression of circadian rhythmicity should therefore
be one of the critical interventions toward slowing down
neurodegeneration caused by neuroinflammatory processes.
Concluding Remarks
Neuroinflammation, processing of APP to the Aβ peptide, tau
protein hyperphosphorylation, relocalization and deposition, are
the leading mechanisms in AD. These processes are propagated
by obesity, the metabolic syndrome and type-2 diabetes mellitus.
Stress, sedentariness, dietary overconsumption of saturated fat
and refined sugar, and circadian derangements/disturbed sleep
all contribute to obesity and related metabolic diseases, but also
accelerate age-related damage and senescence that all feed the
risk of developing AD. It is difficult to make clear separations
between these mechanisms, as they are strongly overlapping and
integrated.
The choice for addressing above-mentioned issues in relation
to the TNF system was provided by its major role in immune
regulation with widespread implications. TNFα is however not
the least complex in this case. Although many mechanisms have
beenmentioned with respect to TNFα, these are probably the “tip
of the iceberg.” This is for example illustrated by the complex
crosstalk that exists between the two TNF-receptors: TNFR1 and
TNFR2. TNFR1 translates mainly proinflammatory signals, while
TNFR2 is thought to primarily be a pro-survival signal (Naude
et al., 2011). Because of the diversity of functions of TNFα, which
is not restricted to either TNFR1 or TNFR2, it becomes very
complex and can be dependent on the temporal dynamics of this
crosstalk and under the given (patho) physiological condition in
which they take place.
As to why AD develops, we speculate that this is initially
an adaptive response of the brain that becomes maladaptive.
Inflammation in the brain, analogous to inflammation in
peripheral organs and tissues, is a response to damage and
requires fuels for restorative actions. Migration of macrophages
and monocytes across the BBB and glial activation are highly
adaptive in this sense too. Weakening of the BBB endothelium in
the obese state allows this migration to occur. The brain requires
glucose for metabolic purposes, however insulin resistance in
certain brain regions makes this a problematic event. The
deficient energy status implicated in the neurodegenerative
pathology has previously been coined “type-3 diabetes mellitus”
(Steen et al., 2005). Thus, a coordinated response of a
chronically injured brain (which we believe occurs with obesity
and particularly with metabolic diseases like type-2 diabetes
mellitus) would be to increase fuel availability by (1) activating
sympathetic nervous system outflow and HPA axis activity,
and (2) promote food consumption. Increased basal and cold-
induced sympathetic and HPA axis activity have indeed been
demonstrated in AD patients (Pascualy et al., 2000). In the
case of obesity and metabolic derangements, these responses
would obviously worsen the etiology of the disease. Besides
glucose, the brain can also utilize ketones for metabolic purposes
(Owen et al., 1967). Ketone bodies are elevated in conditions
of food restriction, and both food restriction as well as ketone
body supplementation are neuroprotective, but hypoglycaemia
(another feature of food restriction) is not neuroprotective
(Davis et al., 2008). Feeding a diet very low in carbohydrates
and usually rich in proteins and fat is also ketogenic, and has
been shown to slow the progression of AD too (Gasior et al.,
2006). The neuroprotective effects may result from enhancing
energy provision by ketones to resist or fight metabolic and
inflammatory challenges (Julio-Amilpas et al., 2015).We propose
here that the brain misinterprets “obesity” for “starvation.”
Thus, both obesity and starvation are characterized –among
others–by shutting down leptin access toward the brain, insulin
resistance, and hypertriglyceridemia, but the compound to
fuel neuronal metabolic processes for repair (i.e., ketones)
is lacking in obesity. For this reason obesity and associated
metabolic disease may underlie an energy crisis in the brain
that leads to an insufficient counteraction of accumulating
damage and finally will increase the risk to develop AD
(see Figure 1).
Sustainable health is important for one’s physical and mental
well-being, social presence and quality of life, apart from the
absence of disease (World Health Organization, 2015a,b), but
this is in first place achieved by making healthy and conscious
lifestyle decisions in which ample exercise and sleep, healthy
dietary habits, and a manageable mental stress level are defining
factors. Eventually, these choices can be traced to a molecular
level and very specifically translated into how and where these
have an action on, but also were they can go awry and eventually
develop into disease. Once a disease -like AD- has developed,
the underlying mechanisms are often obscured. Only studying
the adaptive and maladaptive processes from the earliest possible
stage onwards at the highest level of molecular and temporal
resolution without forgetting the bigger picture in both humans
as well as animal models will eventually unravel the exact
underpinnings of AD.
Frontiers in Neuroscience | www.frontiersin.org 11 May 2015 | Volume 9 | Article 173
van Dijk et al. Metabolic implications on neurodegeneration
References
Aberg, D. (2010). Role of the growth hormone/insulin-like growth factor 1 axis in
neurogenesis. Endocr. Dev. 17, 63–76. doi: 10.1159/000262529
Aberg, N. D., Carlsson, B., Rosengren, L., Oscarsson, J., Isaksson, O. G., Ronnback,
L., et al. (2000). Growth hormone increases connexin-43 expression in
the cerebral cortex and hypothalamus. Endocrinology 141, 3879–3886. doi:
10.1210/en.141.10.3879
Aguiar, A. S. Jr., Castro, A. A., Moreira, E. L., Glaser, V., Santos, A. R., Tasca, C.
I., et al. (2011). Short bouts of mild-intensity physical exercise improve spatial
learning and memory in aging rats: involvement of hippocampal plasticity
via AKT, CREB and BDNF signaling. Mech. Ageing Dev. 132, 560–567. doi:
10.1016/j.mad.2011.09.005
Ahmad, I., Steggles, A. W., Carrillo, A. J., and Finkelstein, J. A. (1989). Obesity-
and sex-related alterations in growth hormonemessenger RNA levels.Mol. Cell.
Endocrinol. 65, 103–109. doi: 10.1016/0303-7207(89)90170-6
Akassoglou, K., Probert, L., Kontogeorgos, G., and Kollias, G. (1997). Astrocyte-
specific but not neuron-specific transmembrane TNF triggers inflammation
and degeneration in the central nervous system of transgenic mice. J. Immunol.
158, 438–445.
Anstey, K. J., Kingston, A., Kiely, K. M., Luszcz, M. A., Mitchell, P., and
Jagger, C. (2014). The influence of smoking, sedentary lifestyle and obesity on
cognitive impairment-free life expectancy. Int. J. Epidemiol. 43, 1874–1883. doi:
10.1093/ije/dyu170
Araujo, D. M., Lapchak, P. A., Collier, B., and Quirion, R. (1989). Localization
of interleukin-2 immunoreactivity and interleukin-2 receptors in the rat
brain: interaction with the cholinergic system. Brain Res. 498, 257–266. doi:
10.1016/0006-8993(89)91104-9
Arrone, L. J., Mackintosh, R., Rosenbaum, M., Leibel, R. L., and Hirsch, J. (1997).
Cardiac autonomic nervous system activity in obese and never-obese young
men. Obes. Res. 5, 354–359. doi: 10.1002/j.1550-8528.1997.tb00564.x
Avena, N. M. (2007). Examining the addictive-like properties of binge eating
using an animal model of sugar dependence. Exp. Clin. Psychopharmacol. 15,
481–491. doi: 10.1037/1064-1297.15.5.481
Bagyinszky, E., Youn, Y. C., An, S. S., and Kim, S. (2014). The genetics of
Alzheimer’s disease. Clin. Interv. Aging 9, 535–551. doi: 10.2147/CIA.S51571
Balasa, B., La Cava, A., Van Gunst, K., Mocnik, L., Balakrishna, D., Nguyen,
N., et al. (2000). A mechanism for IL-10-mediated diabetes in the nonobese
diabetic (NOD) mouse: ICAM-1 deficiency blocks accelerated diabetes.
J. Immunol. 165, 7330–7337. doi: 10.4049/jimmunol.165.12.7330
Banks, W. A. (2005). Blood-brain barrier transport of cytokines: a
mechanism for neuropathology. Curr. Pharm. Des. 11, 973–984. doi:
10.2174/1381612053381684
Banks, W. A., Coon, A. B., Robinson, S. M., Moinuddin, A., Shultz, J. M., Nakaoke,
R., et al. (2004). Triglycerides induce leptin resistance at the blood-brain barrier.
Diabetes 53, 1253–1260. doi: 10.2337/diabetes.53.5.1253
Banks, W. A., Kastin, A. J., Huang, W., Jaspan, J. B., and Maness, L. M. (1996).
Leptin enters the brain by a saturable system independent of insulin. Peptides
17, 305–311. doi: 10.1016/0196-9781(96)00025-3
Banks, W. A., Morley, J. E., Farr, S. A., Price, T. O., Ercal, N., Vidaurre, I.,
et al. (2010). Effects of a growth hormone-releasing hormone antagonist on
telomerase activity, oxidative stress, longevity, and aging in mice. Proc. Natl.
Acad. Sci. U.S.A. 107, 22272–22277. doi: 10.1073/pnas.1016369107
Barberger-Gateau, P., Samieri, C., Feart, C., and Plourde, M. (2011). Dietary
omega 3 polyunsaturated fatty acids and Alzheimer’s disease: interaction
with apolipoprotein E genotype. Curr. Alzheimer Res. 8, 479–491. doi:
10.2174/156720511796391926
Barcia, A. M., and Harris, H. W. (2005). Triglyceride-rich lipoproteins as agents
of innate immunity. Clin. Infect. Dis. 41(Suppl 7), S498–S503. doi: 10.1086/
432005
Bartke, A. (2008). Growth hormone and aging: a challenging controversy. Clin.
Interv. Aging 3, 659–665. doi: 10.2147/CIA.S3697
Baskin, D. G., Stein, L. J., Ikeda, H., Woods, S. C., Figlewicz, D. P., Porte, D. Jr.,
et al. (1985). Genetically obese Zucker rats have abnormally low brain insulin
content. Life Sci. 36, 627–633. doi: 10.1016/0024-3205(85)90166-3
Bazan, N. G. (2007). Omega-3 fatty acids, pro-inflammatory signaling and
neuroprotection. Curr. Opin. Clin. Nutr. Metab. Care 10, 136–141. doi:
10.1097/MCO.0b013e32802b7030
Belayev, L., Khoutorova, L., Atkins, K. D., and Bazan, N. G. (2009).
Robust docosahexaenoic acid-mediated neuroprotection in a rat
model of transient, focal cerebral ischemia. Stroke 40, 3121–3126. doi:
10.1161/STROKEAHA.109.555979
Belkhelfa, M., Rafa, H., Medjeber, O., Arroul-Lammali, A., Behairi, N., Abada-
Bendib, M., et al. (2014). IFN-gamma and TNF-alpha are involved during
Alzheimer disease progression and correlate with nitric oxide production:
a study in Algerian patients. J. Interferon Cytokine Res. 34, 839–847. doi:
10.1089/jir.2013.0085
Benthem, L., Keizer, K., Wiegman, C. H., de Boer, S. F., Strubbe, J. H., Steffens, A.
B., et al. (2000). Excess portal venous long-chain fatty acids induce syndrome
X via HPA axis and sympathetic activation. Am. J. Physiol. Endocrinol. Metab.
279, E1286–E1293.
Bentivoglio, M., Deng, X. H., Nygard, M., Sadki, A., and Kristensson,
K. (2006). The aging suprachiasmatic nucleus and cytokines: functional,
molecular, and cellular changes in rodents. Chronobiol. Int. 23, 437–449. doi:
10.1080/07420520500545797
Berridge, K. C. (2009). ‘Liking’ and ‘wanting’ food rewards: brain substrates
and roles in eating disorders. Physiol. Behav. 97, 537–550. doi:
10.1016/j.physbeh.2009.02.044
Berthoud, H. R. (2011). Metabolic and hedonic drives in the neural control
of appetite: who is the boss? Curr. Opin. Neurobiol. 21, 888–896. doi:
10.1016/j.conb.2011.09.004
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., and Tanzi, R. E. (2007).
Systematic meta-analyses of Alzheimer disease genetic association studies: the
AlzGene database. Nat. Genet. 39, 17–23. doi: 10.1038/ng1934
Bhattacharyya, S., Brown, D. E., Brewer, J. A., Vogt, S. K., and Muglia, L. J. (2007).
Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated
inflammatory responses by selective inhibition of p38 MAP kinase. Blood 109,
4313–4319. doi: 10.1182/blood-2006-10-048215
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., and Scheltens, P. (2006).
Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 5,
64–74. doi: 10.1016/S1474-4422(05)70284-2
Bitar, M. S. (2000). Insulin and glucocorticoid-dependent suppression
of the IGF-I system in diabetic wounds. Surgery 127, 687–695. doi:
10.1067/msy.2000.105869
Bjorntorp, P. (1991). Metabolic implications of body fat distribution.Diabetes Care
14, 1132–1143. doi: 10.2337/diacare.14.12.1132
Blagosklonny,M. V. (2013). Bigmice die young but large animals live longer.Aging
(Albany NY) 5, 227–233.
Borovikova, L. V., Ivanova, S., Zhang, M., Yang, H., Botchkina, G. I., Watkins, L.
R., et al. (2000). Vagus nerve stimulation attenuates the systemic inflammatory
response to endotoxin. Nature 405, 458–462. doi: 10.1038/35013070
Braak, H., and Braak, E. (1991). Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathol. 82, 239–259. doi: 10.1007/BF00308809
Brands, A. M., Biessels, G. J., de Haan, E. H., Kappelle, L. J., and Kessels, R. P.
(2005). The effects of type 1 diabetes on cognitive performance: a meta-analysis.
Diabetes Care 28, 726–735. doi: 10.2337/diacare.28.3.726
Brennan, F. M., Green, P., Amjadi, P., Robertshaw, H. J., Alvarez-Iglesias,
M., and Takata, M. (2008). Interleukin-10 regulates TNF-alpha-converting
enzyme (TACE/ADAM-17) involving a TIMP-3 dependent and independent
mechanism. Eur. J. Immunol. 38, 1106–1117. doi: 10.1002/eji.2007
37821
Brookmeyer, R., Gray, S., and Kawas, C. (1998). Projections of Alzheimer’s disease
in the United States and the public health impact of delaying disease onset. Am.
J. Public Health 88, 1337–1342. doi: 10.2105/AJPH.88.9.1337
Brookmeyer, R., Johnson, E., Ziegler-Graham, K., and Arrighi, H. M. (2007).
Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 3,
186–191. doi: 10.1016/j.jalz.2007.04.381
Bruun, J. M., Verdich, C., Toubro, S., Astrup, A., and Richelsen, B. (2003).
Association between measures of insulin sensitivity and circulating levels
of interleukin-8, interleukin-6 and tumor necrosis factor-alpha. Effect of
weight loss in obese men. Eur. J. Endocrinol. 148, 535–542. doi: 10.1530/eje.0.
1480535
Burns, A., and Iliffe, S. (2009). Alzheimer’s disease. BMJ 338:b158. doi:
10.1136/bmj.b158
Cao, G., Bales, K. R., DeMattos, R. B., and Paul, S. M. (2007). Liver X receptor-
mediated gene regulation and cholesterol homeostasis in brain: relevance
Frontiers in Neuroscience | www.frontiersin.org 12 May 2015 | Volume 9 | Article 173
van Dijk et al. Metabolic implications on neurodegeneration
to Alzheimer’s disease therapeutics. Curr. Alzheimer Res. 4, 179–184. doi:
10.2174/156720507780362173
Cao, L., Choi, E. Y., Liu, X., Martin, A., Wang, C., Xu, X., et al. (2011).
White to brown fat phenotypic switch induced by genetic and environmental
activation of a hypothalamic-adipocyte axis. Cell Metab. 14, 324–338. doi:
10.1016/j.cmet.2011.06.020
Capuron, L., and Miller, A. H. (2011). Immune system to brain signaling:
neuropsychopharmacological implications. Pharmacol. Ther. 130, 226–238.
doi: 10.1016/j.pharmthera.2011.01.014
Castrillo, A., and Tontonoz, P. (2004). Nuclear receptors in macrophage
biology: at the crossroads of lipid metabolism and inflammation. Annu.
Rev. Cell Dev. Biol. 20, 455–480. doi: 10.1146/annurev.cellbio.20.012103.
134432
Cederholm, T., Salem, N. Jr., and Palmblad, J. (2013). omega-3 fatty acids in
the prevention of cognitive decline in humans. Adv. Nutr. 4, 672–676. doi:
10.3945/an.113.004556
Chakravarthy, M. V., and Booth, F. W. (2004). Eating, exercise, and
“thrifty” genotypes: connecting the dots toward an evolutionary
understanding of modern chronic diseases. J. Appl. Physiol. 96, 3–10. doi:
10.1152/japplphysiol.00757.2003
Cohen, S., Janicki-Deverts, D., Doyle, W. J., Miller, G. E., Frank, E., Rabin,
B. S., et al. (2012). Chronic stress, glucocorticoid receptor resistance,
inflammation, and disease risk. Proc. Natl. Acad. Sci. U.S.A. 109, 5995–5999.
doi: 10.1073/pnas.1118355109
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T.
W., Nyce, M. R., et al. (1996). Serum immunoreactive-leptin concentrations
in normal-weight and obese humans. N. Engl. J. Med. 334, 292–295. doi:
10.1056/NEJM199602013340503
Cordido, F., Garcia-Buela, J., Sangiao-Alvarellos, S., Martinez, T., and
Vidal, O. (2010). The decreased growth hormone response to growth
hormone releasing hormone in obesity is associated to cardiometabolic
risk factors. Mediators Inflamm. 2010:434562. doi: 10.1155/2010/
434562
Cotman, C. W. (2005). The role of neurotrophins in brain aging: a
perspective in honor of Regino Perez-Polo. Neurochem. Res. 30, 877–881. doi:
10.1007/s11064-005-6960-y
Craft, S. (2005). Insulin resistance syndrome and Alzheimer’s disease: age-
and obesity-related effects on memory, amyloid, and inflammation.
Neurobiol. Aging 26(Suppl 1), 65–69. doi: 10.1016/j.neurobiolaging.2005.
08.021
Craig, B. W., Brown, R., and Everhart, J. (1989). Effects of progressive
resistance training on growth hormone and testosterone levels in young and
elderly subjects. Mech. Ageing Dev. 49, 159–169. doi: 10.1016/0047-6374(89)
90099-7
Cras, P., Kawai, M., Lowery, D., Gonzalez-DeWhitt, P., Greenberg, B., and
Perry, G. (1991). Senile plaque neurites in Alzheimer disease accumulate
amyloid precursor protein. Proc. Natl. Acad. Sci. U.S.A. 88, 7552–7556. doi:
10.1073/pnas.88.17.7552
Cutuli, D., De Bartolo, P., Caporali, P., Laricchiuta, D., Foti, F., Ronci, M.,
et al. (2014). n-3 polyunsaturated fatty acids supplementation enhances
hippocampal functionality in aged mice. Front. Aging Neurosci. 6:220. doi:
10.3389/fnagi.2014.00220
Dallman, M. F. (2010). Stress-induced obesity and the emotional nervous
system. Trends Endocrinol. Metab. 21, 159–165. doi: 10.1016/j.tem.2009.
10.004
Dallman, M. F., Strack, A. M., Akana, S. F., Bradbury, M. J., Hanson, E. S.,
Scribner, K. A., et al. (1993). Feast and famine: critical role of glucocorticoids
with insulin in daily energy flow. Front. Neuroendocrinol. 14, 303–347. doi:
10.1006/frne.1993.1010
Dandona, P., Aljada, A., and Bandyopadhyay, A. (2004). Inflammation: the link
between insulin resistance, obesity and diabetes. Trends Immunol. 25, 4–7. doi:
10.1016/j.it.2003.10.013
Davidson, T. L., Monnot, A., Neal, A. U., Martin, A. A., Horton, J. J., and
Zheng, W. (2012). The effects of a high-energy diet on hippocampal-
dependent discrimination performance and blood-brain barrier integrity differ
for diet-induced obese and diet-resistant rats. Physiol. Behav. 107, 26–33. doi:
10.1016/j.physbeh.2012.05.015
Davis, J. F., Choi, D. L., and Benoit, S. C. (2010). Insulin, leptin and
reward. Trends Endocrinol. Metab. 21, 68–74. doi: 10.1016/j.tem.2009.
08.004
Davis, L. M., Pauly, J. R., Readnower, R. D., Rho, J. M., and Sullivan, P. G. (2008).
Fasting is neuroprotective following traumatic brain injury. J. Neurosci. Res. 86,
1812–1822. doi: 10.1002/jnr.21628
de Jonge, L., Moreira, E. A., Martin, C. K., Ravussin, E., and Pennington,
C. T. (2010). Impact of 6-month caloric restriction on autonomic nervous
system activity in healthy, overweight, individuals. Obesity 18, 414–416. doi:
10.1038/oby.2009.408
DeKosky, S. T., and Scheff, S. W. (1990). Synapse loss in frontal cortex biopsies
in Alzheimer’s disease: correlation with cognitive severity. Ann. Neurol. 27,
457–464. doi: 10.1002/ana.410270502
D’Ercole, A. J. (1996). Insulin-like growth factors and their receptors in
growth. Endocrinol. Metab. Clin. North Am. 25, 573–590. doi: 10.1016/S0889-
8529(05)70341-8
De Souza, C. T., Araujo, E. P., Bordin, S., Ashimine, R., Zollner, R. L., Boschero, A.
C., et al. (2005). Consumption of a fat-rich diet activates a proinflammatory
response and induces insulin resistance in the hypothalamus. Endocrinology
146, 4192–4199. doi: 10.1210/en.2004-1520
Dhingra, S., Sharma, A. K., Arora, R. C., Slezak, J., and Singal, P. K.
(2009). IL-10 attenuates TNF-alpha-induced NF kappaB pathway activation
and cardiomyocyte apoptosis. Cardiovasc. Res. 82, 59–66. doi: 10.1093/cvr/
cvp040
Dong, H., and Csernansky, J. G. (2009). Effects of stress and stress hormones on
amyloid-beta protein and plaque deposition. J. Alzheimers Dis. 18, 459–469.
doi: 10.3233/JAD-2009-1152
Dournaud, P., Delaere, P., Hauw, J. J., and Epelbaum, J. (1995). Differential
correlation between neurochemical deficits, neuropathology, and cognitive
status in Alzheimer’s disease. Neurobiol. Aging 16, 817–823. doi: 10.1016/0197-
4580(95)00086-T
Doyle, P., Rohner-Jeanrenaud, F., and Jeanrenaud, B. (1993). Local cerebral glucose
utilization in brains of lean and genetically obese (fa/fa) rats.Am. J. Physiol. 264,
E29–E36.
Dubey, A. K., Hanukoglu, A., Hansen, B. C., and Kowarski, A. A. (1988). Metabolic
clearance rates of synthetic human growth hormone in lean and obese male
rhesus monkeys. J. Clin. Endocrinol. Metab. 67, 1064–1067. doi: 10.1210/jcem-
67-5-1064
Dumery, L., Bourdel, F., Soussan, Y., Fialkowsky, A., Viale, S., Nicolas,
P., et al. (2001). beta-Amyloid protein aggregation: its implication in
the physiopathology of Alzheimer’s disease. Pathol. Biol. 49, 72–85. doi:
10.1016/S0369-8114(00)00009-2
Dunaiski, V., and Belford, D. A. (2002). Contribution of circulating IGF-
I to wound repair in GH-treated rats. Growth Horm. IGF Res. 12,
381–387. doi: 10.1016/S1096-6374(02)00080-1
Eikelenboom, P., van Exel, E., Hoozemans, J. J., Veerhuis, R., Rozemuller, A. J.,
and van Gool, W. A. (2010). Neuroinflammation - an early event in both the
history and pathogenesis of Alzheimer’s disease. Neurodegener. Dis. 7, 38–41.
doi: 10.1159/000283480
Eikelenboom, P., Veerhuis, R., Scheper, W., Rozemuller, A. J., van Gool, W.
A., and Hoozemans, J. J. (2006). The significance of neuroinflammation in
understanding Alzheimer’s disease. J. Neural Transm. 113, 1685–1695. doi:
10.1007/s00702-006-0575-6
Emmerzaal, T. L., Kiliaan, A. J., and Gustafson, D. R. (2015). 2003-2013: a decade
of body mass index, Alzheimer’s disease, and dementia. J. Alzheimers Dis. 43,
739–755. doi: 10.3233/JAD-141086
Enhamre-Brolin, E., Carlsson, A., Hallberg, M., and Nyberg, F. (2013).
Growth hormone reverses streptozotocin-induced cognitive impairments
in male mice. Behav. Brain Res. 238, 273–278. doi: 10.1016/j.bbr.2012.
10.036
Eskelinen, M. H., Ngandu, T., Helkala, E. L., Tuomilehto, J., Nissinen, A., Soininen,
H., et al. (2008). Fat intake at midlife and cognitive impairment later in life:
a population-based CAIDE study. Int. J. Geriatr. Psychiatry 23, 741–747. doi:
10.1002/gps.1969
Esteve, E., Ricart, W., and Fernandez-Real, J. M. (2005). Dyslipidemia and
inflammation: an evolutionary conserved mechanism. Clin. Nutr. 24, 16–31.
doi: 10.1016/j.clnu.2004.08.004
Frontiers in Neuroscience | www.frontiersin.org 13 May 2015 | Volume 9 | Article 173
van Dijk et al. Metabolic implications on neurodegeneration
Fain, J. N. (2006). Release of interleukins and other inflammatory cytokines
by human adipose tissue is enhanced in obesity and primarily due to
the nonfat cells. Vitam. Horm. 74, 443–477. doi: 10.1016/S0083-6729(06)
74018-3
Familian, A., Boshuizen, R. S., Eikelenboom, P., and Veerhuis, R. (2006). Inhibitory
effect of minocycline on amyloid beta fibril formation and human microglial
activation. Glia 53, 233–240. doi: 10.1002/glia.20268
Farooqi, I. S., Bullmore, E., Keogh, J., Gillard, J., O’Rahilly, S., and Fletcher, P.
C. (2007). Leptin regulates striatal regions and human eating behavior. Science
317, 1355. doi: 10.1126/science.1144599
Feingold, K. R., Adi, S., Staprans, I., Moser, A. H., Neese, R., Verdier, J. A.,
et al. (1990). Diet affects the mechanisms by which TNF stimulates hepatic
triglyceride production. Am. J. Physiol. 259, E177–E184.
Fischer, R., Maier, O., Siegemund, M., Wajant, H., Scheurich, P., and
Pfizenmaier, K. (2011). A TNF receptor 2 selective agonist rescues human
neurons from oxidative stress-induced cell death. PLoS ONE 6:e27621. doi:
10.1371/journal.pone.0027621
Fitzpatrick, S., Gilbert, S., and Serpell, L. (2013). Systematic review: are overweight
and obese individuals impaired on behavioural tasks of executive functioning?
Neuropsychol. Rev. 23, 138–156. doi: 10.1007/s11065-013-9224-7
Folli, F., Ghidella, S., Bonfanti, L., Kahn, C. R., and Merighi, A. (1996). The
early intracellular signaling pathway for the insulin/insulin-like growth factor
receptor family in the mammalian central nervous system.Mol. Neurobiol. 13,
155–183. doi: 10.1007/BF02740639
Freeman, L. R., Haley-Zitlin, V., Rosenberger, D. S., and Granholm, A. C.
(2014). Damaging effects of a high-fat diet to the brain and cognition:
a review of proposed mechanisms. Nutr. Neurosci. 17, 241–251. doi:
10.1179/1476830513Y.0000000092
Freeman, L. R., Zhang, L., Nair, A., Dasuri, K., Francis, J., Fernandez-Kim, S.
O., et al. (2013). Obesity increases cerebrocortical reactive oxygen species
and impairs brain function. Free Radic. Biol. Med. 56, 226–233. doi:
10.1016/j.freeradbiomed.2012.08.577
Fuente-Martin, E., Garcia-Caceres, C., Granado, M., de Ceballos, M. L., Sanchez-
Garrido, M. A., Sarman, B., et al. (2012). Leptin regulates glutamate and glucose
transporters in hypothalamic astrocytes. J. Clin. Invest. 122, 3900–3913. doi:
10.1172/JCI64102
Gao, Q., and Horvath, T. L. (2008). Neuronal control of energy homeostasis. FEBS
Lett. 582, 132–141. doi: 10.1016/j.febslet.2007.11.063
Garcia-Aragon, J., Lobie, P. E., Muscat, G. E., Gobius, K. S., Norstedt, G.,
and Waters, M. J. (1992). Prenatal expression of the growth hormone (GH)
receptor/binding protein in the rat: a role for GH in embryonic and fetal
development? Development 114, 869–876.
Gasior, M., Rogawski, M. A., and Hartman, A. L. (2006). Neuroprotective and
disease-modifying effects of the ketogenic diet. Behav. Pharmacol. 17, 431–439.
doi: 10.1097/00008877-200609000-00009
Gavillet, M., Allaman, I., and Magistretti, P. J. (2008). Modulation of astrocytic
metabolic phenotype by proinflammatory cytokines. Glia 56, 975–989. doi:
10.1002/glia.20671
Ghanim, H., Monte, S. V., Sia, C. L., Abuaysheh, S., Green, K., Caruana, J.
A., et al. (2012). Reduction in inflammation and the expression of amyloid
precursor protein and other proteins related to Alzheimer’s disease following
gastric bypass surgery. J. Clin. Endocrinol. Metab. 97, E1197–E1201. doi:
10.1210/jc.2011-3284
Giordano, C. R., Terlecky, L. J., Bollig-Fischer, A., Walton, P. A., and Terlecky, S.
R. (2014). Amyloid-beta neuroprotection mediated by a targeted antioxidant.
Sci. Rep. 4:4983. doi: 10.1038/srep04983
Godfrey, R. J., Madgwick, Z., and Whyte, G. P. (2003). The exercise-induced
growth hormone response in athletes. Sports Med. 33, 599–613. doi:
10.2165/00007256-200333080-00005
Goossens, G. H., and Blaak, E. E. (2012). Adipose tissue oxygen tension:
implications for chronic metabolic and inflammatory diseases. Curr. Opin.
Clin. Nutr. Metab. Care 15, 539–546. doi: 10.1097/MCO.0b013e3283
58fa87
Grant, R. W., and Dixit, V. D. (2015). Adipose tissue as an immunological organ.
Obesity 23, 512–518. doi: 10.1002/oby.21003
Grassi, G., Facchini, A., Trevano, F. Q., Dell’Oro, R., Arenare, F., Tana,
F., et al. (2005). Obstructive sleep apnea-dependent and -independent
adrenergic activation in obesity. Hypertension 46, 321–325. doi:
10.1161/01.HYP.0000174243.39897.6c
Greenberg, A. S., and Obin, M. S. (2006). Obesity and the role of adipose tissue in
inflammation and metabolism. Am. J. Clin. Nutr. 83, 461S–465S.
Grillo, C. A., Piroli, G. G., Rosell, D. R., Hoskin, E. K., McEwen, B. S., and Reagan,
L. P. (2003). Region specific increases in oxidative stress and superoxide
dismutase in the hippocampus of diabetic rats subjected to stress. Neuroscience
121, 133–140. doi: 10.1016/S0306-4522(03)00343-9
Gupta, S., Bi, R., Kim, C., Chiplunkar, S., Yel, L., and Gollapudi, S. (2005). Role
of NF-kappaB signaling pathway in increased tumor necrosis factor-alpha-
induced apoptosis of lymphocytes in aged humans. Cell Death Differ. 12,
177–183. doi: 10.1038/sj.cdd.4401557
Gustafson, B. (2010). Adipose tissue, inflammation and atherosclerosis.
J. Atheroscler. Thromb. 17, 332–341. doi: 10.5551/jat.3939
Haan, M. N. (2006). Therapy Insight: type 2 diabetes mellitus and the risk
of late-onset Alzheimer’s disease. Nat. Clin. Pract. Neurol. 2, 159–166. doi:
10.1038/ncpneuro0124
Hanci, M., Kuday, C., and Oguzoglu, S. A. (1994). The effects of synthetic growth
hormone on spinal cord injury. J. Neurosurg. Sci. 38, 43–49.
Hanzel, C. E., Pichet-Binette, A., Pimentel, L. S., Iulita, M. F., Allard, S.,
Ducatenzeiler, A., et al. (2014). Neuronal driven pre-plaque inflammation in
a transgenic rat model of Alzheimer’s disease. Neurobiol. Aging 35, 2249–2262.
doi: 10.1016/j.neurobiolaging.2014.03.026
Harris, H. W., Gosnell, J. E., and Kumwenda, Z. L. (2000). The lipemia of sepsis:
triglyceride-rich lipoproteins as agents of innate immunity. J. Endotoxin Res. 6,
421–430. doi: 10.1179/096805100101532351
Hattiangady, B., Rao, M. S., Shetty, G. A., and Shetty, A. K. (2005). Brain-derived
neurotrophic factor, phosphorylated cyclic AMP response element binding
protein and neuropeptide Y decline as early as middle age in the dentate gyrus
and CA1 and CA3 subfields of the hippocampus. Exp. Neurol. 195, 353–371.
doi: 10.1016/j.expneurol.2005.05.014
He, P., Zhong, Z., Lindholm, K., Berning, L., Lee, W., Lemere, C., et al.
(2007). Deletion of tumor necrosis factor death receptor inhibits amyloid beta
generation and prevents learning and memory deficits in Alzheimer’s mice.
J. Cell Biol. 178, 829–841. doi: 10.1083/jcb.200705042
Ho, K. K., and Hoffman, D. M. (1993). Aging and growth hormone.Horm. Res. 40,
80–86. doi: 10.1159/000183771
Ho, L., Qin, W., Pompl, P. N., Xiang, Z., Wang, J., Zhao, Z., et al. (2004). Diet-
induced insulin resistance promotes amyloidosis in a transgenic mouse model
of Alzheimer’s disease. FASEB J. 18, 902–904. doi: 10.1096/fj.03-0978fje
Hoebel, B. G., Avena, N. M., Bocarsly, M. E., and Rada, P. (2009). Natural
addiction: a behavioral and circuit model based on sugar addiction in rats.
J. Addict. Med. 3, 33–41. doi: 10.1097/ADM.0b013e31819aa621
Hojlund, K., Frystyk, J., Levin, K., Flyvbjerg, A., Wojtaszewski, J. F., and Beck-
Nielsen, H. (2006). Reduced plasma adiponectin concentrationsmay contribute
to impaired insulin activation of glycogen synthase in skeletal muscle of
patients with type 2 diabetes. Diabetologia 49, 1283–1291. doi: 10.1007/s00125-
006-0240-5
Hotamisligil, G. S., Arner, P., Caro, J. F., Atkinson, R. L., and Spiegelman, B.
M. (1995). Increased adipose tissue expression of tumor necrosis factor-alpha
in human obesity and insulin resistance. J. Clin. Invest 95, 2409–2415. doi:
10.1172/JCI117936
Hut, R. A., and Van der Zee, E. A. (2011). The cholinergic system, circadian
rhythmicity, and time memory. Behav. Brain Res. 221, 466–480. doi:
10.1016/j.bbr.2010.11.039
Inoue, J., Ishida, T., Tsukamoto, N., Kobayashi, N., Naito, A., Azuma, S.,
et al. (2000). Tumor necrosis factor receptor-associated factor (TRAF) family:
adapter proteins that mediate cytokine signaling. Exp. Cell Res. 254, 14–24. doi:
10.1006/excr.1999.4733
Jaeger, L. B., Dohgu, S., Sultana, R., Lynch, J. L., Owen, J. B., Erickson, M. A., et al.
(2009). Lipopolysaccharide alters the blood-brain barrier transport of amyloid
beta protein: a mechanism for inflammation in the progression of Alzheimer’s
disease. Brain Behav. Immun. 23, 507–517. doi: 10.1016/j.bbi.2009.01.017
James, M. J., Gibson, R. A., and Cleland, L. G. (2000). Dietary polyunsaturated fatty
acids and inflammatory mediator production.Am. J. Clin. Nutr. 71, 343S–348S.
Jang, I. S., Hwang, D. Y., Chae, K. R., Lee, J. E., Kim, Y. K., Kang, T. S.,
et al. (2003). Role of dietary fat type in the development of adiposity from
Frontiers in Neuroscience | www.frontiersin.org 14 May 2015 | Volume 9 | Article 173
van Dijk et al. Metabolic implications on neurodegeneration
dietary obesity-susceptible Sprague-Dawley rats. Br. J. Nutr. 89, 429–438. doi:
10.1079/BJN2002801
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., and Butler, P. C.
(2004). Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53,
474–481. doi: 10.2337/diabetes.53.2.474
Jayaraman, A., Lent-Schochet, D., and Pike, C. J. (2014). Diet-induced obesity
and low testosterone increase neuroinflammation and impair neural function.
J. Neuroinflammation 11, 162. doi: 10.1186/s12974-014-0162-y
Jiang, Q., Lee, C. Y., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., et al.
(2008). ApoE promotes the proteolytic degradation of Abeta. Neuron 58,
681–693. doi: 10.1016/j.neuron.2008.04.010
Jiao, J., Li, Q., Chu, J., Zeng, W., Yang, M., and Zhu, S. (2014). Effect of n-3
PUFA supplementation on cognitive function throughout the life span from
infancy to old age: a systematic review and meta-analysis of randomized
controlled trials. Am. J. Clin. Nutr. 100, 1422–1436. doi: 10.3945/ajcn.114.
095315
Julio-Amilpas, A., Montiel, T., Soto-Tinoco, E., Geronimo-Olvera, C., and
Massieu, L. (2015). Protection of hypoglycemia-induced neuronal death by
beta-hydroxybutyrate involves the preservation of energy levels and decreased
production of reactive oxygen species. J. Cereb. Blood FlowMetab. 35, 851–860.
doi: 10.1038/jcbfm.2015.1
Kaiyala, K. J., Prigeon, R. L., Kahn, S. E., Woods, S. C., and Schwartz, M. W.
(2000). Obesity induced by a high-fat diet is associated with reduced brain
insulin transport in dogs. Diabetes 49, 1525–1533. doi: 10.2337/diabetes.49.
9.1525
Kalmijn, S., Feskens, E. J., Launer, L. J., and Kromhout, D. (1997). Polyunsaturated
fatty acids, antioxidants, and cognitive function in very old men. Am. J.
Epidemiol. 145, 33–41. doi: 10.1093/oxfordjournals.aje.a009029
Kanaley, J. A. (2008). Growth hormone, arginine and exercise. Curr. Opin. Clin.
Nutr. Metab. Care 11, 50–54. doi: 10.1097/MCO.0b013e3282f2b0ad
Kennedy, G. C. (1953). The role of depot fat in the hypothalamic control of
food intake in the rat. Proc. R. Soc. Lond. B Biol. Sci. 140, 578–596. doi:
10.1098/rspb.1953.0009
Kim, B., Backus, C., Oh, S., Hayes, J. M., and Feldman, E. L. (2009). Increased tau
phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes.
Endocrinology 150, 5294–5301. doi: 10.1210/en.2009-0695
Kivipelto, M., Helkala, E. L., Laakso, M. P., Hanninen, T., Hallikainen, M.,
Alhainen, K., et al. (2001). Midlife vascular risk factors and Alzheimer’s disease
in later life: longitudinal, population based study. BMJ 322, 1447–1451. doi:
10.1136/bmj.322.7300.1447
Kmiec, Z. (2001). Cooperation of liver cells in health and disease. Adv. Anat.
Embryol. Cell Biol. 161 III–XIII, 1–151. doi: 10.1007/978-3-642-56553-3_7
Koekkoek, P. S., Rutten, G. E., and Biessels, G. J. (2014). Cognitive disorders in
diabetic patients. Handb. Clin. Neurol. 126, 145–166. doi: 10.1016/B978-0-444-
53480-4.00011-4
Kohman, R. A., DeYoung, E. K., Bhattacharya, T. K., Peterson, L. N., and Rhodes,
J. S. (2012). Wheel running attenuates microglia proliferation and increases
expression of a proneurogenic phenotype in the hippocampus of aged mice.
Brain Behav. Immun. 26, 803–810. doi: 10.1016/j.bbi.2011.10.006
Kontermann, R. E., Munkel, S., Neumeyer, J., Muller, D., Branschadel,
M., Scheurich, P., et al. (2008). A humanized tumor necrosis factor
receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition
of tumor necrosis factor (TNF) action. J. Immunother. 31, 225–234. doi:
10.1097/CJI.0b013e31816a88f9
Kooistra, M., Geerlings, M. I., Mali, W. P., Vincken, K. L., van der Graaf, Y.,
Biessels, G. J., et al. (2013). Diabetes mellitus and progression of vascular brain
lesions and brain atrophy in patients with symptomatic atherosclerotic disease.
The SMART-MR study. J. Neurol. Sci. 332, 69–74. doi: 10.1016/j.jns.2013.
06.019
Koolhaas, J. M., Bartolomucci, A., Buwalda, B., de Boer, S. F., Flugge, G.,
Korte, S. M., et al. (2011). Stress revisited: a critical evaluation of the stress
concept.Neurosci. Biobehav. Rev. 35, 1291–1301. doi: 10.1016/j.neubiorev.2011.
02.003
Kranzler, J. H., Rosenbloom, A. L., Martinez, V., and Guevara-Aguirre, J. (1998).
Normal intelligence with severe insulin-like growth factor I deficiency due
to growth hormone receptor deficiency: a controlled study in a genetically
homogeneous population. J. Clin. Endocrinol. Metab. 83, 1953–1958. doi:
10.1210/jc.83.6.1953
Krstic, D., and Knuesel, I. (2013). Deciphering the mechanism underlying
late-onset Alzheimer disease. Nat. Rev. Neurol. 9, 25–34. doi:
10.1038/nrneurol.2012.236
Kudlow, P. A., Cha, D. S., Lam, R.W., andMcIntyre, R. S. (2013). Sleep architecture
variation: a mediator of metabolic disturbance in individuals with major
depressive disorder. Sleep Med. 14, 943–949. doi: 10.1016/j.sleep.2013.04.017
Labrousse, V. F., Nadjar, A., Joffre, C., Costes, L., Aubert, A., Gregoire, S., et al.
(2012). Short-term long chain omega3 diet protects from neuroinflammatory
processes and memory impairment in aged mice. PLoS ONE 7:e36861. doi:
10.1371/journal.pone.0036861
Laitinen, M. H., Ngandu, T., Rovio, S., Helkala, E. L., Uusitalo, U., Viitanen,
M., et al. (2006). Fat intake at midlife and risk of dementia and Alzheimer’s
disease: a population-based study. Dement. Geriatr. Cogn. Disord. 22, 99–107.
doi: 10.1159/000093478
Landry, G. J., and Liu-Ambrose, T. (2014). Buying time: a rationale for examining
the use of circadian rhythm and sleep interventions to delay progression of mild
cognitive impairment to Alzheimer’s disease. Front. Aging Neurosci. 6:325. doi:
10.3389/fnagi.2014.00325
Leise, T. L., Harrington, M. E., Molyneux, P. C., Song, I., Queenan, H.,
Zimmerman, E., et al. (2013). Voluntary exercise can strengthen the circadian
system in aged mice. Age 35, 2137–2152. doi: 10.1007/s11357-012-9502-y
Levin, B. E. (1993). Sympathetic activity, age, sucrose preference, and diet-induced
obesity. Obes. Res. 1, 281–287. doi: 10.1002/j.1550-8528.1993.tb00622.x
Li, R. C., Guo, S. Z., Raccurt, M., Moudilou, E., Morel, G., Brittian, K.
R., et al. (2011). Exogenous growth hormone attenuates cognitive deficits
induced by intermittent hypoxia in rats. Neuroscience 196, 237–250. doi:
10.1016/j.neuroscience.2011.08.029
Lionetti, L., Mollica, M. P., Lombardi, A., Cavaliere, G., Gifuni, G., and Barletta,
A. (2009). From chronic overnutrition to insulin resistance: the role of fat-
storing capacity and inflammation. Nutr. Metab. Cardiovasc. Dis. 19, 146–152.
doi: 10.1016/j.numecd.2008.10.010
Liu, C. C., Kanekiyo, T., Xu, H., and Bu, G. (2013). Apolipoprotein E and
Alzheimer disease: risk, mechanisms and therapy.Nat. Rev. Neurol. 9, 106–118.
doi: 10.1038/nrneurol.2012.263
Liu, Y., Liu, F., Grundke-Iqbal, I., Iqbal, K., and Gong, C. X. (2009). Brain
glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes
and Alzheimer’s disease. J. Neurochem. 111, 242–249. doi: 10.1111/j.1471-
4159.2009.06320.x
Lobie, P. E., Garcia-Aragon, J., Lincoln, D. T., Barnard, R., Wilcox, J. N., and
Waters, M. J. (1993). Localization and ontogeny of growth hormone receptor
gene expression in the central nervous system. Brain Res. Dev. Brain Res. 74,
225–233. doi: 10.1016/0165-3806(93)90008-X
Lu, T., Pan, Y., Kao, S. Y., Li, C., Kohane, I., Chan, J., et al. (2004). Gene regulation
and DNA damage in the ageing human brain. Nature 429, 883–891. doi:
10.1038/nature02661
Luiten, P. G., ter Horst, G. J., Karst, H., and Steffens, A. B. (1985). The
course of paraventricular hypothalamic efferents to autonomic structures in
medulla and spinal cord. Brain Res. 329, 374–378. doi: 10.1016/0006-8993(85)
90554-2
Lumeng, C. N., and Saltiel, A. R. (2011). Inflammatory links between obesity
and metabolic disease. J. Clin. Invest. 121, 2111–2117. doi: 10.1172/
JCI57132
Magistretti, P. J., and Pellerin, L. (1999). Cellular mechanisms of brain energy
metabolism and their relevance to functional brain imaging. Philos. Trans. R.
Soc. Lond. B Biol. Sci. 354, 1155–1163. doi: 10.1098/rstb.1999.0471
Makimura, H., Stanley, T., Mun, D., You, S. M., and Grinspoon, S. (2008). The
effects of central adiposity on growth hormone (GH) response to GH-releasing
hormone-arginine stimulation testing in men. J. Clin. Endocrinol. Metab. 93,
4254–4260. doi: 10.1210/jc.2008-1333
Makki, K., Froguel, P., andWolowczuk, I. (2013). Adipose tissue in obesity-related
inflammation and insulin resistance: cells, cytokines, and chemokines. ISRN
Inflamm. 2013:139239. doi: 10.1155/2013/139239
Malone, J. I., Hanna, S., Saporta, S., Mervis, R. F., Park, C. R., Chong, L.,
et al. (2008). Hyperglycemia not hypoglycemia alters neuronal dendrites and
impairs spatial memory. Pediatr. Diabetes 9, 531–539. doi: 10.1111/j.1399-
5448.2008.00431.x
Marcell, T. J., Wiswell, R. A., Hawkins, S. A., and Tarpenning, K. M. (1999).
Age-related blunting of growth hormone secretion during exercise may not be
Frontiers in Neuroscience | www.frontiersin.org 15 May 2015 | Volume 9 | Article 173
van Dijk et al. Metabolic implications on neurodegeneration
soley due to increased somatostatin tone. Metab. Clin. Exp. 48, 665–670. doi:
10.1016/S0026-0495(99)90069-0
Marchetti, L., Klein, M., Schlett, K., Pfizenmaier, K., and Eisel, U. L. (2004). Tumor
necrosis factor (TNF)-mediated neuroprotection against glutamate-induced
excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation.
Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-
dependent NF-kappa B pathway. J. Biol. Chem. 279, 32869–32881. doi:
10.1074/jbc.M311766200
Marino, J. S., Xu, Y., and Hill, J. W. (2011). Central insulin and leptin-mediated
autonomic control of glucose homeostasis. Trends Endocrinol. Metab. 22,
275–285. doi: 10.1016/j.tem.2011.03.001
Marosi, K., Bori, Z., Hart, N., Sarga, L., Koltai, E., Radak, Z., et al. (2012). Long-
term exercise treatment reduces oxidative stress in the hippocampus of aging
rats. Neuroscience 226, 21–28. doi: 10.1016/j.neuroscience.2012.09.001
Mattson, M. P., and Magnus, T. (2006). Ageing and neuronal vulnerability. Nat.
Rev. Neurosci. 7, 278–294. doi: 10.1038/nrn1886
McAllister, E. J., Dhurandhar, N. V., Keith, S. W., Aronne, L. J., Barger, J., Baskin,
M., et al. (2009). Ten putative contributors to the obesity epidemic. Crit. Rev.
Food Sci. Nutr. 49, 868–913. doi: 10.1080/10408390903372599
McCoy, M. K., and Tansey, M. G. (2008). TNF signaling inhibition in the
CNS: implications for normal brain function and neurodegenerative disease.
J. Neuroinflammation 5:45. doi: 10.1186/1742-2094-5-45
McEwen, B. S., and Reagan, L. P. (2004). Glucose transporter expression in the
central nervous system: relationship to synaptic function. Eur. J. Pharmacol.
490, 13–24. doi: 10.1016/j.ejphar.2004.02.041
McEwen, B. S., andWingfield, J. C. (2003). The concept of allostasis in biology and
biomedicine. Horm. Behav. 43, 2–15. doi: 10.1016/S0018-506X(02)00024-7
Moller, D. E. (2000). Potential role of TNF-alpha in the pathogenesis of insulin
resistance and type 2 diabetes. Trends Endocrinol. Metab. 11, 212–217. doi:
10.1016/S1043-2760(00)00272-1
Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., and Wilson,
R. S. (2004). Dietary fat intake and 6-year cognitive change in an
older biracial community population. Neurology 62, 1573–1579. doi:
10.1212/01.WNL.0000123250.82849.B6
Mulder, C. K., Gerkema, M. P., and Van der Zee, E. A. (2013). Circadian
clocks and memory: time-place learning. Front. Mol. Neurosci. 6:8. doi:
10.3389/fnmol.2013.00008
Nathan, C. (2002). Points of control in inflammation. Nature 420, 846–852. doi:
10.1038/nature01320
Naude, P. J., den Boer, J. A., Luiten, P. G., and Eisel, U. L. (2011). Tumor
necrosis factor receptor cross-talk. FEBS J. 278, 888–898. doi: 10.1111/j.1742-
4658.2011.08017.x
Neumann, H., Kotter, M. R., and Franklin, R. J. (2009). Debris clearance by
microglia: an essential link between degeneration and regeneration. Brain 132,
288–295. doi: 10.1093/brain/awn10
Norman, G. J., Karelina, K., Zhang, N., Walton, J. C., Morris, J. S., and Devries, A.
C. (2010). Stress and IL-1beta contribute to the development of depressive-like
behavior following peripheral nerve injury. Mol. Psychiatry 15, 404–414. doi:
10.1038/mp.2009.91
Ogawa, S., Lozach, J., Benner, C., Pascual, G., Tangirala, R. K., Westin, S., et al.
(2005). Molecular determinants of crosstalk between nuclear receptors and
toll-like receptors. Cell 122, 707–721. doi: 10.1016/j.cell.2005.06.029
Ohta, H., Wada, H., Niwa, T., Kirii, H., Iwamoto, N., Fujii, H., et al. (2005).
Disruption of tumor necrosis factor-alpha gene diminishes the development
of atherosclerosis in ApoE-deficient mice. Atherosclerosis 180, 11–17. doi:
10.1016/j.atherosclerosis.2004.11.016
O’Neill, C. (2013). PI3-kinase/Akt/mTOR signaling: impaired on/off switches in
aging, cognitive decline and Alzheimer’s disease. Exp. Gerontol. 48, 647–653.
doi: 10.1016/j.exger.2013.02.025
Orr, S. K., Trepanier, M. O., and Bazinet, R. P. (2013). n-3 Polyunsaturated fatty
acids in animal models with neuroinflammation. Prostaglandins Leukot. Essent.
Fatty Acids 88, 97–103. doi: 10.1016/j.plefa.2012.05.008
Owen, O. E.,Morgan, A. P., Kemp,H. G., Sullivan, J.M., Herrera,M. G., and Cahill,
G. F. Jr. (1967). Brain metabolism during fasting. J. Clin. Invest. 46, 1589–1595.
doi: 10.1172/JCI105650
Pan, W., Stone, K. P., Hsuchou, H., Manda, V. K., Zhang, Y., and Kastin, A.
J. (2011). Cytokine signaling modulates blood-brain barrier function. Curr.
Pharm. Des. 17, 3729–3740. doi: 10.2174/138161211798220918
Park, S. E., Dantzer, R., Kelley, K. W., and McCusker, R. H. (2011).
Central administration of insulin-like growth factor-I decreases depressive-like
behavior and brain cytokine expression inmice. J. Neuroinflammation 8:12. doi:
10.1186/1742-2094-8-12
Pascualy, M., Petrie, E. C., Brodkin, K., Peskind, E. R., Wilkinson, C. W., and
Raskind, M. A. (2000). Hypothalamic pituitary adrenocortical and sympathetic
nervous system responses to the cold pressor test in Alzheimer’s disease. Biol.
Psychiatry 48, 247–254. doi: 10.1016/S0006-3223(00)00879-9
Patel, A. B., Lai, J. C., Chowdhury, G. M., Hyder, F., Rothman, D. L.,
Shulman, R. G., et al. (2014). Direct evidence for activity-dependent
glucose phosphorylation in neurons with implications for the astrocyte-to-
neuron lactate shuttle. Proc. Natl. Acad. Sci. U.S.A. 111, 5385–5390. doi:
10.1073/pnas.1403576111
Pavlov, V. A., and Tracey, K. J. (2012). The vagus nerve and the inflammatory
reflex–linking immunity andmetabolism.Nat. Rev. Endocrinol. 8, 743–754. doi:
10.1038/nrendo.2012.189
Permana, P. A., Menge, C., and Reaven, P. D. (2006). Macrophage-secreted factors
induce adipocyte inflammation and insulin resistance. Biochem. Biophys. Res.
Commun. 341, 507–514. doi: 10.1016/j.bbrc.2006.01.012
Petersen, A. M., and Pedersen, B. K. (2005). The anti-inflammatory effect of
exercise. J. Appl. Physiol. 98, 1154–1162. doi: 10.1152/japplphysiol.00164.2004
Picardi, P. K., Caricilli, A. M., de Abreu, L. L., Carvalheira, J. B., Velloso, L.
A., and Saad, M. J. (2010). Modulation of hypothalamic PTP1B in the TNF-
alpha-induced insulin and leptin resistance. FEBS Lett. 584, 3179–3184. doi:
10.1016/j.febslet.2010.05.064
Popa, C., Netea, M. G., van Riel, P. L., van der Meer, J. W., and Stalenhoef,
A. F. (2007). The role of TNF-alpha in chronic inflammatory conditions,
intermediarymetabolism, and cardiovascular risk. J. Lipid Res. 48, 751–762. doi:
10.1194/jlr.R600021-JLR200
Posey, K. A., Clegg, D. J., Printz, R. L., Byun, J., Morton, G. J., Vivekanandan-
Giri, A., et al. (2009). Hypothalamic proinflammatory lipid accumulation,
inflammation, and insulin resistance in rats fed a high-fat diet. Am. J. Physiol.
Endocrinol. Metab. 296, E1003–E1012. doi: 10.1152/ajpendo.90377.2008
Prasad, M. R., Lovell, M. A., Yatin, M., Dhillon, H., and Markesbery, W. R.
(1998). Regional membrane phospholipid alterations in Alzheimer’s disease.
Neurochem. Res. 23, 81–88. doi: 10.1023/A:1022457605436
Pritzlaff, C. J., Wideman, L., Blumer, J., Jensen, M., Abbott, R. D., Gaesser, G. A.,
et al. (2000). Catecholamine release, growth hormone secretion, and energy
expenditure during exercise vs. recovery in men. J. Appl. Physiol. 89, 937–946.
Profenno, L. A., Porsteinsson, A. P., and Faraone, S. V. (2010). Meta-analysis
of Alzheimer’s disease risk with obesity, diabetes, and related disorders. Biol.
Psychiatry 67, 505–512. doi: 10.1016/j.biopsych.2009.02.013
Puglielli, L., Tanzi, R. E., and Kovacs, D. M. (2003). Alzheimer’s disease: the
cholesterol connection. Nat. Neurosci. 6, 345–351. doi: 10.1038/nn0403-345
Querfurth, H. W., and LaFerla, F. M. (2010). Alzheimer’s disease. N. Engl. J. Med.
362, 329–344. doi: 10.1056/NEJMra0909142
Rajpathak, S. N., Gunter, M. J., Wylie-Rosett, J., Ho, G. Y., Kaplan, R. C.,
Muzumdar, R., et al. (2009). The role of insulin-like growth factor-I and its
binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab.
Res. Rev. 25, 3–12. doi: 10.1002/dmrr.919
Rath, P. C., and Aggarwal, B. B. (1999). TNF-induced signaling in apoptosis. J. Clin.
Immunol. 19, 350–364. doi: 10.1023/A:1020546615229
Reader, B. F., Jarrett, B. L., McKim, D. B., Wohleb, E. S., Godbout, J. P., and
Sheridan, J. F. (2015). Peripheral and central effects of repeated social defeat
stress: monocyte trafficking, microglial activation, and anxiety. Neuroscience
289C, 429–442. doi: 10.1016/j.neuroscience.2015.01.001
Roenneberg, T., Allebrandt, K. V., Merrow, M., and Vetter, C. (2012). Social jetlag
and obesity. Curr. Biol. 22, 939–943. doi: 10.1016/j.cub.2012.03.038
Rosenbaum, M., and Leibel, R. L. (2014). 20 years of leptin: role of leptin in energy
homeostasis in humans. J. Endocrinol. 223, T83–T96. doi: 10.1530/JOE-14-
0358
Ruiz-Torres, A., and Soares de Melo Kirzner, M. (2002). Ageing and longevity are
related to growth hormone/insulin-like growth factor-1 secretion. Gerontology
48, 401–407. doi: 10.1159/000065507
Sadki, A., Bentivoglio, M., Kristensson, K., and Nygard, M. (2007). Suppressors,
receptors and effects of cytokines on the aging mouse biological clock.
Neurobiol. Aging 28, 296–305. doi: 10.1016/j.neurobiolaging.2005.
12.007
Frontiers in Neuroscience | www.frontiersin.org 16 May 2015 | Volume 9 | Article 173
van Dijk et al. Metabolic implications on neurodegeneration
Salles, J., Tardif, N., Landrier, J. F., Mothe-Satney, I., Guillet, C., Boue-Vaysse, C.,
et al. (2012). TNFalpha gene knockout differentially affects lipid deposition in
liver and skeletal muscle of high-fat-diet mice. J. Nutr. Biochem. 23, 1685–1693.
doi: 10.1016/j.jnutbio.2011.12.001
Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M.,
et al. (2005). Tau suppression in a neurodegenerative mouse model improves
memory function. Science 309, 476–481. doi: 10.1126/science.1113694
Scheepens, A., Sirimanne, E. S., Breier, B. H., Clark, R. G., Gluckman, P. D., and
Williams, C. E. (2001). Growth hormone as a neuronal rescue factor during
recovery from CNS injury. Neuroscience 104, 677–687. doi: 10.1016/S0306-
4522(01)00109-9
Schroeter, M. L., Stein, T., Maslowski, N., and Neumann, J. (2009). Neural
correlates of Alzheimer’s disease and mild cognitive impairment: a systematic
and quantitative meta-analysis involving 1351 patients. Neuroimage 47,
1196–1206. doi: 10.1016/j.neuroimage.2009.05.037
Schwartz, M. W., Woods, S. C., Porte, D. Jr., Seeley, R. J., and Baskin, D. G.
(2000). Central nervous system control of food intake. Nature 404, 661–671.
doi: 10.1038/35007534
Seaquist, E. R., Damberg, G. S., Tkac, I., and Gruetter, R. (2001). The
effect of insulin on in vivo cerebral glucose concentrations and rates
of glucose transport/metabolism in humans. Diabetes 50, 2203–2209. doi:
10.2337/diabetes.50.10.2203
Sebert, S. P., Lecannu, G., Kozlowski, F., Siliart, B., Bard, J. M., Krempf, M.,
et al. (2005). Childhood obesity and insulin resistance in a Yucatan mini-piglet
model: putative roles of IGF-1 and muscle PPARs in adipose tissue activity and
development. Int. J. Obes. 29, 324–333. doi: 10.1038/sj.ijo.0802823
Shytle, R. D., Mori, T., Townsend, K., Vendrame, M., Sun, N., Zeng, J., et al. (2004).
Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors.
J. Neurochem. 89, 337–343. doi: 10.1046/j.1471-4159.2004.02347.x
Signore, A. P., Zhang, F., Weng, Z., Gao, Y., and Chen, J. (2008). Leptin
neuroprotection in the CNS: mechanisms and therapeutic potentials.
J. Neurochem. 106, 1977–1990. doi: 10.1111/j.1471-4159.2008.05457.x
Sims-Robinson, C., Kim, B., Rosko, A., and Feldman, E. L. (2010). How does
diabetes accelerate Alzheimer disease pathology? Nat. Rev. Neurol. 6, 551–559.
doi: 10.1038/nrneurol.2010.130
Singh, K. P., Prasad, R., Chari, P. S., and Dash, R. J. (1998). Effect of growth
hormone therapy in burn patients on conservative treatment. Burns 24,
733–738.
Skrapari, I., Tentolouris, N., Perrea, D., Bakoyiannis, C., Papazafiropoulou, A.,
and Katsilambros, N. (2007). Baroreflex sensitivity in obesity: relationship
with cardiac autonomic nervous system activity. Obesity 15, 1685–1693. doi:
10.1038/oby.2007.201
Song, E., Fan, P., Huang, B., Deng, H. B., Cheung, B. M., Feletou, M.,
et al. (2014). Deamidated lipocalin-2 induces endothelial dysfunction and
hypertension in dietary obese mice. J. Am. Heart Assoc. 3:e000837. doi:
10.1161/JAHA.114.000837
Soscia, S. J., Kirby, J. E., Washicosky, K. J., Tucker, S. M., Ingelsson, M., Hyman,
B., et al. (2010). The Alzheimer’s disease-associated amyloid beta-protein is an
antimicrobial peptide. PLoS ONE 5:e9505. doi: 10.1371/journal.pone.0009505
Speakman, J. R. (2006). Thrifty genes for obesity and themetabolic syndrome–time
to call off the search? Diab. Vasc. Dis. Res. 3, 7–11. doi: 10.3132/dvdr.2006.010
Srivareerat, M., Tran, T. T., Alzoubi, K. H., and Alkadhi, K. A. (2009).
Chronic psychosocial stress exacerbates impairment of cognition and long-
term potentiation in beta-amyloid rat model of Alzheimer’s disease. Biol.
Psychiatry 65, 918–926. doi: 10.1016/j.biopsych.2008.08.021
Staels, B. (2006). When the Clock stops ticking, metabolic syndrome explodes.
Nature medicine 12, 54–55; discussion 55. doi: 10.1038/nm0106-54
Steen, E., Terry, B. M., Rivera, E. J., Cannon, J. L., Neely, T. R., Tavares,
R., et al. (2005). Impaired insulin and insulin-like growth factor expression
and signaling mechanisms in Alzheimer’s disease–is this type 3 diabetes?
J. Alzheimers Dis. 7, 63–80.
Steyn, F. J., Xie, T. Y., Huang, L., Ngo, S. T., Veldhuis, J. D., Waters, M. J.,
et al. (2013). Increased adiposity and insulin correlates with the progressive
suppression of pulsatile GH secretion during weight gain. J. Endocrinol. 218,
233–244. doi: 10.1530/JOE-13-0084
Stranahan, A. M., Norman, E. D., Lee, K., Cutler, R. G., Telljohann, R. S., Egan, J.
M., et al. (2008). Diet-induced insulin resistance impairs hippocampal synaptic
plasticity and cognition in middle-aged rats. Hippocampus 18, 1085–1088. doi:
10.1002/hipo.20470
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild,
J., Salvesen, G. S., et al. (1993). Apolipoprotein E: high-avidity binding
to beta-amyloid and increased frequency of type 4 allele in late-onset
familial Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90, 1977–1981. doi:
10.1073/pnas.90.5.1977
Suh, Y. H., and Checler, F. (2002). Amyloid precursor protein, presenilins, and
alpha-synuclein: molecular pathogenesis and pharmacological applications in
Alzheimer’s disease. Pharmacol. Rev. 54, 469–525. doi: 10.1124/pr.54.3.469
Suzuki, H., Park, S. J., Tamura, M., and Ando, S. (1998). Effect of the long-
term feeding of dietary lipids on the learning ability, fatty acid composition
of brain stem phospholipids and synaptic membrane fluidity in adult mice:
a comparison of sardine oil diet with palm oil diet. Mech. Ageing Dev. 101,
119–128. doi: 10.1016/S0047-6374(97)00169-3
Takach, O., Gill, T. B., and Silverman, M. A. (2015). Modulation of insulin
signaling rescues BDNF transport defects independent of tau in amyloid-beta
oligomer-treated hippocampal neurons. Neurobiol. Aging 36, 1378–1382. doi:
10.1016/j.neurobiolaging.2014.11.018
Takada, Y., Fang, X., Jamaluddin, M. S., Boyd, D. D., and Aggarwal, B. B. (2004).
Genetic deletion of glycogen synthase kinase-3beta abrogates activation of
IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis
induced by tumor necrosis factor. J. Biol. Chem. 279, 39541–39554. doi:
10.1074/jbc.M403449200
Takeuchi, O., and Akira, S. (2010). Pattern recognition receptors and
inflammation. Cell 140, 805–820. doi: 10.1016/j.cell.2010.01.022
Tanzi, R. E. (1999). A genetic dichotomy model for the inheritance of Alzheimer’s
disease and common age-related disorders. J. Clin. Invest. 104, 1175–1179. doi:
10.1172/JCI8593
Teerds, K. J., de Rooij, D. G., and Keijer, J. (2011). Functional relationship between
obesity and male reproduction: from humans to animal models. Hum. Reprod.
Update 17, 667–683. doi: 10.1093/humupd/dmr017
Thaler, J. P., and Schwartz, M. W. (2010). Minireview: inflammation and obesity
pathogenesis: the hypothalamus heats up. Endocrinology 151, 4109–4115. doi:
10.1210/en.2010-0336
Thaler, J. P., Yi, C. X., Schur, E. A., Guyenet, S. J., Hwang, B. H., Dietrich, M.
O., et al. (2012). Obesity is associated with hypothalamic injury in rodents and
humans. J. Clin. Invest 122, 153–162. doi: 10.1172/JCI59660
Timmermans, S., Bogie, J. F., Vanmierlo, T., Lutjohann, D., Stinissen, P., Hellings,
N., et al. (2014). High fat diet exacerbates neuroinflammation in an animal
model of multiple sclerosis by activation of the Renin Angiotensin system.
J. Neuroimmune Pharmacol. 9, 209–217. doi: 10.1007/s11481-013-9502-4
Tolppanen, A.M., Ngandu, T., Kareholt, I., Laatikainen, T., Rusanen,M., Soininen,
H., et al. (2014). Midlife and late-life body mass index and late-life dementia:
results from a prospective population-based cohort. J. Alzheimers Dis. 38,
201–209. doi: 10.3233/JAD-130698
Tracey, K. J. (2007). Physiology and immunology of the cholinergic
antiinflammatory pathway. J. Clin. Invest 117, 289–296. doi: 10.1172/JCI30555
Trejo, J. L., Carro, E., Garcia-Galloway, E., and Torres-Aleman, I. (2004). Role
of insulin-like growth factor I signaling in neurodegenerative diseases. J. Mol.
Med. 82, 156–162. doi: 10.1007/s00109-003-0499-7
Trejo, J. L., Carro, E., Nunez, A., and Torres-Aleman, I. (2002).
Sedentary life impairs self-reparative processes in the brain: the role
of serum insulin-like growth factor-I. Rev. Neurosci. 13, 365–374. doi:
10.1515/REVNEURO.2002.13.4.365
Trejo, J. L., Piriz, J., Llorens-Martin, M. V., Fernandez, A. M., Bolos, M., LeRoith,
D., et al. (2007). Central actions of liver-derived insulin-like growth factor
I underlying its pro-cognitive effects. Mol. Psychiatry 12, 1118–1128. doi:
10.1038/sj.mp.4002076
Tsigos, C., Kyrou, I., Chala, E., Tsapogas, P., Stavridis, J. C., Raptis, S. A.,
et al. (1999). Circulating tumor necrosis factor alpha concentrations are
higher in abdominal versus peripheral obesity.Metabolism 48, 1332–1335. doi:
10.1016/S0026-0495(99)90277-9
Tulipano, G., Taylor, J. E., Halem, H. A., Datta, R., Dong, J. Z., Culler, M.
D., et al. (2007). Glucocorticoid inhibition of growth in rats: partial reversal
with the full-length ghrelin analog BIM-28125. Pituitary 10, 267–274. doi:
10.1007/s11102-007-0054-6
Frontiers in Neuroscience | www.frontiersin.org 17 May 2015 | Volume 9 | Article 173
van Dijk et al. Metabolic implications on neurodegeneration
Unger, R. H., and Scherer, P. E. (2010). Gluttony, sloth and the metabolic
syndrome: a roadmap to lipotoxicity. Trends Endocrinol. Metab. 21, 345–352.
doi: 10.1016/j.tem.2010.01.00
Urayama, A., and Banks, W. A. (2008). Starvation and triglycerides reverse the
obesity-induced impairment of insulin transport at the blood-brain barrier.
Endocrinology 149, 3592–3597. doi: 10.1210/en.2008-0008
Vahl, N., Jorgensen, J. O., Skjaerbaek, C., Veldhuis, J. D., Orskov, H., and
Christiansen, J. S. (1997). Abdominal adiposity rather than age and sex predicts
mass and regularity of GH secretion in healthy adults. Am. J. Physiol. 272,
E1108–E1116.
Vainik, U., Dagher, A., Dube, L., and Fellows, L. K. (2013). Neurobehavioural
correlates of body mass index and eating behaviours in adults:
a systematic review. Neurosci. Biobehav. Rev. 37, 279–299. doi:
10.1016/j.neubiorev.2012.11.008
Van der Zee, E. A., Jansen, K., and Gerkema, M. P. (1999). Severe loss of
vasopressin-immunoreactive cells in the suprachiasmatic nucleus of aging voles
coincides with reduced circadian organization of running wheel activity. Brain
Res. 816, 572–579. doi: 10.1016/S0006-8993(98)01239-6
Vaz, M., Jennings, G., Turner, A., Cox, H., Lambert, G., and Esler, M.
(1997). Regional sympathetic nervous activity and oxygen consumption
in obese normotensive human subjects. Circulation 96, 3423–3429. doi:
10.1161/01.CIR.96.10.3423
Veldhuis, J. D., Metzger, D. L., Martha, P. M. Jr., Mauras, N., Kerrigan, J. R.,
Keenan, B., et al. (1997). Estrogen and testosterone, but not a nonaromatizable
androgen, direct network integration of the hypothalamo-somatotrope (growth
hormone)-insulin-like growth factor I axis in the human: evidence from
pubertal pathophysiology and sex-steroid hormone replacement. J. Clin.
Endocrinol. Metab. 82, 3414–3420. doi: 10.1210/jc.82.10.3414
Vonck, K., Raedt, R., Naulaerts, J., De Vogelaere, F., Thiery, E., Van Roost, D.,
et al. (2014). Vagus nerve stimulation...25 years later! What do we know
about the effects on cognition? Neurosci. Biobehav. Rev. 45, 63–71. doi:
10.1016/j.neubiorev.2014.05.005
Vykoukal, D., and Davies, M. G. (2011). Vascular biology of metabolic syndrome.
J. Vasc. Surg. 54, 819–831. doi: 10.1016/j.jvs.2011.01.003
Wajant, H., Pfizenmaier, K., and Scheurich, P. (2003). Tumor necrosis factor
signaling. Cell Death Differ. 10, 45–65. doi: 10.1038/sj.cdd.4401189
Wang, B., and Trayhurn, P. (2006). Acute and prolonged effects of TNF-
alpha on the expression and secretion of inflammation-related adipokines by
human adipocytes differentiated in culture. Pflugers Archiv 452, 418–427. doi:
10.1007/s00424-006-0055-8
Wang, H., Yu, M., Ochani, M., Amella, C. A., Tanovic, M., Susarla, S., et al. (2003).
Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of
inflammation. Nature 421, 384–388. doi: 10.1038/nature01339
Wang, Y., Lam, K. S., Kraegen, E. W., Sweeney, G., Zhang, J., Tso, A. W., et al.
(2007). Lipocalin-2 is an inflammatory marker closely associated with obesity,
insulin resistance, and hyperglycemia in humans. Clin. Chem. 53, 34–41. doi:
10.1373/clinchem.2006.075614
Wang, Y. Y., Lin, S. Y., Chuang, Y. H., Chen, C. J., Tung, K. C., and Sheu, W.
H. (2011). Adipose proinflammatory cytokine expression through sympathetic
system is associated with hyperglycemia and insulin resistance in a rat
ischemic stroke model. Am. J. Physiol. Endocrinol. Metab. 300, E155–E163. doi:
10.1152/ajpendo.00301.2010
Weinert, D. (2000). Age-dependent changes of the circadian system. Chronobiol.
Int. 17, 261–283. doi: 10.1081/CBI-100101048
Wideman, L., Weltman, J. Y., Hartman, M. L., Veldhuis, J. D., and Weltman,
A. (2002). Growth hormone release during acute and chronic aerobic
and resistance exercise: recent findings. Sports Med. 32, 987–1004. doi:
10.2165/00007256-200232150-00003
Winer, D. A., Winer, S., Shen, L., Wadia, P. P., Yantha, J., Paltser, G., et al. (2011). B
cells promote insulin resistance through modulation of T cells and production
of pathogenic IgG antibodies. Nat. Med. 17, 610–617. doi: 10.1038/nm.2353
Winkler, T., Sharma, H. S., Stalberg, E., Badgaiyan, R. D., Westman, J., and
Nyberg, F. (2000). Growth hormone attenuates alterations in spinal cord
evoked potentials and cell injury following trauma to the rat spinal cord. An
experimental study using topical application of rat growth hormone. Amino
Acids 19, 363–371. doi: 10.1007/s007260070067
Winocur, G., Greenwood, C. E., Piroli, G. G., Grillo, C. A., Reznikov, L. R., Reagan,
L. P., et al. (2005). Memory impairment in obese Zucker rats: an investigation of
cognitive function in an animal model of insulin resistance and obesity. Behav.
Neurosci. 119, 1389–1395. doi: 10.1037/0735-7044.119.5.1389
Winston, B. W., Krein, P. M., Mowat, C., and Huang, Y. (1999). Cytokine-induced
macrophage differentiation: a tale of 2 genes. Clin. Invest. Med. 22, 236–255.
Wischik, C. M., Novak, M., Thogersen, H. C., Edwards, P. C., Runswick, M. J.,
Jakes, R., et al. (1988). Isolation of a fragment of tau derived from the core of
the paired helical filament of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 85,
4506–4510. doi: 10.1073/pnas.85.12.4506
Wisor, J. P., Schmidt, M. A., and Clegern, W. C. (2011). Evidence for
neuroinflammatory and microglial changes in the cerebral response to sleep
loss. Sleep 34, 261–272.
Wohleb, E. S., McKim, D. B., Sheridan, J. F., and Godbout, J. P. (2014b). Monocyte
trafficking to the brain with stress and inflammation: a novel axis of immune-
to-brain communication that influences mood and behavior. Front. Neurosci.
8:447. doi: 10.3389/fnins.2014.0044
Wohleb, E. S., Patterson, J. M., Sharma, V., Quan, N., Godbout, J. P., and Sheridan,
J. F. (2014a). Knockdown of interleukin-1 receptor type-1 on endothelial
cells attenuated stress-induced neuroinflammation and prevented anxiety-like
behavior. J. Neurosci. 34, 2583–2591. doi: 10.1523/JNEUROSCI.3723-13.2014
Woo, J. (2011). Nutritional strategies for successful aging. Med. Clin. North Am.
95, 477–493, ix-x. doi: 10.1016/j.mcna.2011.02.009
Wood, I. S., de Heredia, F. P., Wang, B., and Trayhurn, P. (2009). Cellular hypoxia
and adipose tissue dysfunction in obesity. Proc. Nutr. Soc. 68, 370–377. doi:
10.1017/S0029665109990206
Woods, J. A., Wilund, K. R., Martin, S. A., and Kistler, B. M. (2012). Exercise,
inflammation and aging. Aging Dis. 3, 130–140.
Woods, S. C., Seeley, R. J., Rushing, P. A., D’Alessio, D., and Tso, P. (2003).
A controlled high-fat diet induces an obese syndrome in rats. J. Nutr. 133,
1081–1087.
World Health Organization. (2015a). Obesity and Overweight. Geneva: Fact sheet
311.
World Health Organization. (2015b). Diabetes. Geneva: Fact sheet 312.k
Xiong, X. Q., Chen, W. W., Han, Y., Zhou, Y. B., Zhang, F., Gao, X. Y.,
et al. (2012). Enhanced adipose afferent reflex contributes to sympathetic
activation in diet-induced obesity hypertension. Hypertension 60, 1280–1286.
doi: 10.1161/HYPERTENSIONAHA.112.198002
Xu, W. L., Atti, A. R., Gatz, M., Pedersen, N. L., Johansson, B., and
Fratiglioni, L. (2011). Midlife overweight and obesity increase late-life
dementia risk: a population-based twin study. Neurology 76, 1568–1574. doi:
10.1212/WNL.0b013e3182190d09
Yamamoto, H., Sohmiya, M., Oka, N., and Kato, Y. (1991). Effects of aging and
sex on plasma insulin-like growth factor I (IGF-I) levels in normal adults. Acta
Endocrinol. 124, 497–500. doi: 10.1530/acta.0.1240497
Yamane, K., Ihn, H., Asano, Y., Jinnin, M., and Tamaki, K. (2003). Antagonistic
effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-
beta receptor type II in human dermal fibroblasts. J. Immunol. 171, 3855–3862.
doi: 10.4049/jimmunol.171.7.3855
Yamauchi, T., Hara, K., Kubota, N., Terauchi, Y., Tobe, K., Froguel, P., et al.
(2003). Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-
atherogenic adipokine. Curr. Drug Targets Immune Endocr. Metabol. Disord. 3,
243–254. doi: 10.2174/1568008033340090
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., et al. (2001).
The fat-derived hormone adiponectin reverses insulin resistance associated
with both lipoatrophy and obesity. Nat. Med. 7, 941–946. doi: 10.1038/90984
Yan, H., Mitschelen, M., Bixler, G. V., Brucklacher, R. M., Farley, J. A., Han, S., et al.
(2011). Circulating IGF1 regulates hippocampal IGF1 levels and brain gene
expression during adolescence. J. Endocrinol. 211, 27–37. doi: 10.1530/JOE-11-
0200
Ye, J. (2009). Emerging role of adipose tissue hypoxia in obesity and insulin
resistance. Int. J. Obes. 33, 54–66. doi: 10.1038/ijo.2008.229
Yehuda, S. (2012). Polyunsaturated fatty acids as putative cognitive enhancers.
Med. Hypotheses 79, 456–461. doi: 10.1016/j.mehy.2012.06.021
Yi, C. X., Al-Massadi, O., Donelan, E., Lehti, M., Weber, J., Ress, C., et al. (2012).
Exercise protects against high-fat diet-induced hypothalamic inflammation.
Physiol. Behav. 106, 485–490. doi: 10.1016/j.physbeh.2012.03.021
Zeltser, L. M., Seeley, R. J., and Tschop, M. H. (2012). Synaptic plasticity in
neuronal circuits regulating energy balance. Nat. Neurosci. 15, 1336–1342. doi:
10.1038/nn.3219
Frontiers in Neuroscience | www.frontiersin.org 18 May 2015 | Volume 9 | Article 173
van Dijk et al. Metabolic implications on neurodegeneration
Zendedel, A., Habib, P., Dang, J., Lammerding, L., Hoffmann, S., Beyer, C., et al.
(2015). Omega-3 polyunsaturated fatty acids ameliorate neuroinflammation
and mitigate ischemic stroke damage through interactions with astrocytes
and microglia. J. Neuroimmunol. 278, 200–211. doi: 10.1016/j.jneuroim.2014.
11.007
Zettlitz, K. A., Lorenz, V., Landauer, K., Munkel, S., Herrmann, A., Scheurich, P.,
et al. (2010). ATROSAB, a humanized antagonistic anti-tumor necrosis factor
receptor one-specific antibody.MAbs 2, 639–647. doi: 10.4161/mabs.2.6.13583
Zhang, H., Han, M., Zhang, X., Sun, X., and Ling, F. (2014). The
effect and mechanism of growth hormone replacement on cognitive
function in rats with traumatic brain injury. PLoS ONE 9:e108518. doi:
10.1371/journal.pone.0108518
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., and Friedman, J. M.
(1994). Positional cloning of the mouse obese gene and its human homologue.
Nature 372, 425–432. doi: 10.1038/372425a0
Zhao, E., Tranovich, M. J., and Wright, V. J. (2014). The role of mobility as
a protective factor of cognitive functioning in aging adults: a review. Sports
Health 6, 63–69. doi: 10.1177/1941738113477832
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 van Dijk, van Heijningen, Reijne, Nyakas, van der Zee and Eisel.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Neuroscience | www.frontiersin.org 19 May 2015 | Volume 9 | Article 173
